Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Nephrotic syndrome								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			
Polyuria								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			
Renal mass								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Strangury								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Stress urinary incontinence								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Urethral stenosis								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			
Urinary tract inflammation								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Urinary tract obstruction								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Psychiatric disorders								
All								
Insulin naïve	30	(2.3)	33	2.74	23	(1.7)	25	2.14
Basal insulin	4	(1.5)	5	3.22	5	(1.9)	5	3.27
Basal-bolus insulin regimen	2	(0.7)	2	1.20	9	(3.1)	9	5.40

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Insomnia								
Insulin naïve	7	(0.5)	7	0.59	5	(0.4)	6	0.56
Basal insulin	3	(1.1)	3	1.93	0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Depression								
Insulin naïve	6	(0.5)	6	0.45	5	(0.4)	5	0.37
Basal insulin	1	(0.4)	1	0.64	2	(0.8)	2	1.31
Basal-bolus insulin regimen	1	(0.3)	1	0.60	2	(0.7)	2	1.20
Anxiety								
Insulin naïve	5	(0.4)	5	0.43	6	(0.5)	6	0.44
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Sleep disorder								
Insulin naïve	4	(0.3)	4	0.30	1	(0.1)	1	0.13
Basal insulin	0				2	(0.8)	2	1.31
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Irritability								
Insulin naïve	2	(0.2)	2	0.20	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Agitation								
Insulin naïve	1	(0.1)	1	0.13	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Drug abuse								
Insulin naïve	1	(0.1)	1	0.13	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Depressed mood								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Nightmare								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Adjustment disorder with mixed anxiety and depressed mood								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Disorientation								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Listless								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Post-traumatic stress disorder								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Stress								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Adjustment disorder								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			
Adjustment disorder with depressed mood								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Affect lability								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Anxiety disorder								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Bruxism								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Drug dependence								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Emotional distress								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Basal-bolus insulin regimen	0				0			
Fear								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				2	(0.7)	2	1.20
Major depression								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Mental status changes								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Mixed anxiety and depressive disorder								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Mood swings								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Persistent depressive disorder								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Phobia								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Blood and lymphatic system disorders								
All								
Insulin naïve	25	(1.9)	25	2.20	24	(1.8)	24	2.01
Basal insulin	1	(0.4)	3	1.93	1	(0.4)	1	0.65
Basal-bolus insulin regimen	7	(2.4)	7	4.18	5	(1.7)	5	3.00
Anaemia								
Insulin naïve	15	(1.1)	15	1.40	11	(0.8)	11	0.94
Basal insulin	1	(0.4)	3	1.93	0			
Basal-bolus insulin regimen	3	(1.0)	3	1.79	3	(1.0)	3	1.80
Eosinophilia								
Insulin naïve	2	(0.2)	2	0.15	1	(0.1)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	1	(0.3)	1	0.60
Lymphadenopathy								
Insulin naïve	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Leukopenia								
Insulin naïve	1	(0.1)	1	0.13	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Iron deficiency anaemia								
Insulin naïve	1	(0.1)	1	0.08	2	(0.2)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	1	(0.3)	1	0.60
Polycythaemia								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Thrombocytopenia								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Leukocytosis								
Insulin naïve	1	(0.1)	1	0.07	3	(0.2)	3	0.22
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Splenomegaly								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Blood loss anaemia								
Insulin naïve	0				2	(0.2)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Hypochromic anaemia								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Lymphadenopathy mediastinal								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normocytic anaemia								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Pancytopenia								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Thrombocytosis								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
Insulin naïve	24	(1.8)	32	2.72	20	(1.5)	31	2.46
Basal insulin	3	(1.1)	3	1.93	4	(1.5)	4	2.62
Basal-bolus insulin regimen	4	(1.4)	4	2.39	3	(1.0)	5	3.00
Seborrhoeic keratosis								
Insulin naïve	2	(0.2)	3	0.23	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Adenocarcinoma pancreas								
Insulin naïve	2	(0.2)	2	0.20	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Colon adenoma								
Insulin naïve	2	(0.2)	2	0.20	0			
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			
Colorectal cancer								
Insulin naïve	2	(0.2)	2	0.20	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Metastases to liver								
Insulin naïve	2	(0.2)	2	0.15	1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Bladder papilloma								
Insulin naïve	1	(0.1)	1	0.13	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Lung cancer metastatic								
Insulin naïve	1	(0.1)	1	0.13	1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Skin papilloma								
Insulin naïve	1	(0.1)	1	0.13	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Acrochordon								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Basal cell carcinoma								
Insulin naïve	1	(0.1)	1	0.08	3	(0.2)	3	0.23
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Glioblastoma multiforme								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Haemangioma of liver								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Neoplasm skin								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Oral fibroma								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Pancreatic neoplasm								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Prostate cancer								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Salivary gland neoplasm								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Bladder cancer								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Eye naevus								
Insulin naïve	1	(0.1)	2	0.15	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Invasive ductal breast carcinoma								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Invasive lobular breast carcinoma								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Lipoma								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Pancreatic carcinoma								
Insulin naïve	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Renal neoplasm								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Squamous cell carcinoma of skin								
Insulin naïve	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Adenocarcinoma of colon								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Adrenal adenoma								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Benign renal neoplasm								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Bowen's disease								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Breast cancer								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Breast cancer metastatic								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Chronic myeloid leukaemia								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			
Colon cancer								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Colon cancer stage II								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Dysplastic naevus								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Endometrial adenocarcinoma								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Gastric cancer								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Basal-bolus insulin regimen	0				0			
Gastrointestinal tract adenoma								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hepatocellular carcinoma								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Invasive breast carcinoma								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Lung adenocarcinoma								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Lymphangioma								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Malignant melanoma								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Malignant melanoma in situ								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Malignant peritoneal neoplasm								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Metastases to bone marrow								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Metastases to lymph nodes								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Myxoma								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Osteoma								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Ovarian cancer metastatic								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Pancreatic carcinoma metastatic								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Prostatic adenoma								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Renal cell carcinoma								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Renal hamartoma								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Small cell lung cancer								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Small intestine neuroendocrine tumour								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Uterine cancer								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Uterine leiomyoma								
Insulin naïve	0				2	(0.2)	2	0.15

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Reproductive system and breast disorders								
All								
Insulin naïve	24	(1.8)	24	2.07	19	(1.4)	23	1.82
Basal insulin	4	(1.5)	4	2.58	2	(0.8)	2	1.31
Basal-bolus insulin regimen	1	(0.3)	1	0.60	2	(0.7)	2	1.20
Erectile dysfunction								
Insulin naïve	4	(0.3)	4	0.30	1	(0.1)	1	0.13
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			
Benign prostatic hyperplasia								
Insulin naïve	3	(0.2)	3	0.22	2	(0.2)	2	0.15
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	1	(0.3)	1	0.60
Intermenstrual bleeding								
Insulin naïve	2	(0.2)	2	0.26	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Uterine polyp								
Insulin naïve	2	(0.2)	2	0.15	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Breast pain								
Insulin naïve	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Menstruation delayed								
Insulin naïve	1	(0.1)	1	0.13	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Prostatic calcification								
Insulin naïve	1	(0.1)	1	0.13	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Breast mass								
Insulin naïve	1	(0.1)	1	0.08	1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Menopausal symptoms								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Ovarian cyst								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Pruritus genital								
Insulin naïve	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Uterine prolapse								
Insulin naïve	1	(0.1)	1	0.08	1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Vulvovaginal pruritus								
Insulin naïve	1	(0.1)	1	0.08	2	(0.2)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Atrophic vulvovaginitis								
Insulin naïve	1	(0.1)	1	0.07	1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Ejaculation failure								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Menstruation irregular								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Pelvic discomfort								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Cervical polyp								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			
Colpocele								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Basal-bolus insulin regimen	0				0			
Dysmenorrhoea								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Galactorrhoea								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Genital prolapse								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Menopausal disorder								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Penile rash								
Insulin naïve	0				1	(0.1)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Prostatitis								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Testicular cyst								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Uterine enlargement								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Vaginal discharge								
Insulin naïve	0				2	(0.2)	2	0.20
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Vaginal haemorrhage								
Insulin naïve	0				2	(0.2)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vulvovaginal dryness								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Ear and labyrinth disorders								
All								
Insulin naïve	21	(1.6)	24	1.95	13	(1.0)	14	1.11
Basal insulin	4	(1.5)	4	2.58	4	(1.5)	4	2.62
Basal-bolus insulin regimen	1	(0.3)	1	0.60	5	(1.7)	5	3.00
Vertigo								
Insulin naïve	8	(0.6)	9	0.78	5	(0.4)	6	0.46
Basal insulin	2	(0.8)	2	1.29	1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				2	(0.7)	2	1.20
Ear pain								
Insulin naïve	4	(0.3)	4	0.35	0			
Basal insulin	1	(0.4)	1	0.64	1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Tinnitus								
Insulin naïve	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Deafness bilateral								
Insulin naïve	2	(0.2)	2	0.15	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Vertigo positional								
Insulin naïve	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Ear inflammation								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Eustachian tube dysfunction								
Insulin naïve	1	(0.1)	1	0.08	1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
External ear pain								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypoacusis								
Insulin naïve	1	(0.1)	1	0.07	3	(0.2)	3	0.22
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			
Meniere's disease								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Cerumen impaction								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	1	(0.3)	1	0.60
Deafness unilateral								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Ear discomfort								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Middle ear inflammation								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Motion sickness								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Presbyacusis								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hepatobiliary disorders								
All								
Insulin naïve	15	(1.1)	20	1.67	16	(1.2)	18	1.51
Basal insulin	2	(0.8)	2	1.29	1	(0.4)	1	0.65
Basal-bolus insulin regimen	2	(0.7)	3	1.79	4	(1.4)	6	3.60
Hepatic steatosis								
Insulin naïve	8	(0.6)	8	0.66	8	(0.6)	8	0.70
Basal insulin	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Cholelithiasis								
Insulin naïve	3	(0.2)	3	0.22	1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Cholecystitis								
Insulin naïve	1	(0.1)	1	0.13	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hepatic function abnormal								
Insulin naïve	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Gallbladder cholesterolosis								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hypertransaminasaemia								
Insulin naïve	1	(0.1)	2	0.15	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Liver disorder								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Non-alcoholic steatohepatitis								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hepatic mass								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hepatomegaly								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Alcoholic liver disease								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bile duct stone								
Insulin naïve	0				1	(0.1)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Biliary colic								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Biliary dyskinesia								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Cholecystitis chronic								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	1	(0.3)	1	0.60
Gallbladder polyp								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Hepatic cirrhosis								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Hepatic cyst								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hyperplastic cholecystopathy								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Nonalcoholic fatty liver disease								
Insulin naïve	0				2	(0.2)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Steatohepatitis								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Immune system disorders								
All								
Insulin naïve	7	(0.5)	8	0.60	8	(0.6)	9	0.79
Basal insulin	2	(0.8)	2	1.29	5	(1.9)	5	3.27
Basal-bolus insulin regimen	3	(1.0)	3	1.79	2	(0.7)	2	1.20
Seasonal allergy								
Insulin naïve	6	(0.5)	6	0.45	4	(0.3)	4	0.31
Basal insulin	1	(0.4)	1	0.64	2	(0.8)	2	1.31
Basal-bolus insulin regimen	1	(0.3)	1	0.60	2	(0.7)	2	1.20
Allergy to arthropod bite								
Insulin naïve	1	(0.1)	1	0.08	1	(0.1)	1	0.13
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Food allergy								
Insulin naïve	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Allergy to arthropod sting								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Anaphylactic reaction								
Insulin naïve	0				0			
Basal insulin	1	(0.4)	1	0.64	1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Drug hypersensitivity								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Hypersensitivity								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Immunisation reaction								
Insulin naïve	0				1	(0.1)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Congenital, familial and genetic disorders								
All								
Insulin naïve	5	(0.4)	5	0.54	5	(0.4)	5	0.42
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Type V hyperlipidaemia								
Insulin naïve	3	(0.2)	3	0.34	1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Cystic fibrosis lung								
Insulin naïve	1	(0.1)	1	0.13	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hydrocele								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Atrial septal defect								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Congenital syphilitic osteochondritis								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Corneal dystrophy								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Hypertrophic cardiomyopathy								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Myotonic dystrophy								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Endocrine disorders								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
Insulin naïve	4	(0.3)	4	0.30	14	(1.1)	14	1.15
Basal insulin	0				3	(1.1)	3	1.96
Basal-bolus insulin regimen	2	(0.7)	2	1.20	1	(0.3)	1	0.60
Thyroid mass								
Insulin naïve	2	(0.2)	2	0.15	2	(0.2)	2	0.20
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Autoimmune thyroiditis								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hypothyroidism								
Insulin naïve	1	(0.1)	1	0.07	3	(0.2)	3	0.22
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Adrenal mass								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Adrenocortical insufficiency acute								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Goitre								
Insulin naïve	0				2	(0.2)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hyperplasia adrenal								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hyperprolactinaemia								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Hyperthyroidism								
Insulin naïve	0				2	(0.2)	2	0.15
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypogonadism								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Inappropriate antidiuretic hormone secretion								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Secondary hypogonadism								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Surgical and medical procedures								
All								
Insulin naïve	2	(0.2)	2	0.15	4	(0.3)	4	0.30
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	2	(0.7)	2	1.20	1	(0.3)	1	0.60
Knee operation								
Insulin naïve	1	(0.1)	1	0.08	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Cardiac pacemaker replacement								
Insulin naïve	1	(0.1)	1	0.07	0			
Basal insulin	0				0			
Basal-bolus insulin regimen	0				1	(0.3)	1	0.60
Large intestinal polypectomy								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Removal of foreign body								
Insulin naïve	0				1	(0.1)	1	0.08
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Shoulder operation								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			


%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin neoplasm excision								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Spinal operation								
Insulin naïve	0				1	(0.1)	1	0.07
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Toe amputation								
Insulin naïve	0				0			
Basal insulin	0				1	(0.4)	1	0.65
Basal-bolus insulin regimen	0				0			
Tooth extraction								
Insulin naïve	0				0			
Basal insulin	0				0			
Basal-bolus insulin regimen	1	(0.3)	1	0.60	0			
Social circumstances								
All								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			
Menopause								
Insulin naïve	0				1	(0.1)	1	0.13
Basal insulin	0				0			
Basal-bolus insulin regimen	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.77 Adverse events by pre-trial insulin treatment and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 and 6 contribute. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): PRINSTR; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS PRINSTR; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:00:11 - faedotgrp/faesocgrpinsulindotontp3asas.png

7.7.78 Adverse events by pre-trial insulin treatment and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital, Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): PRINSTR; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS PRINSTR; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:00:15 - faedotgrp/faesocgrpinsulindotontt2dsas.png

7.7.79 Adverse events by pre-trial insulin treatment and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 and 6 contribute. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): PRINSTR; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD PRINSTR; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:00:20 - faedotgrp/faept5pctgrpinsulindotontp3asas.png

7.7.80 Adverse events by pre-trial insulin treatment and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool



% of subjects: Percentage of subjects with one or more events, N: Number of subjects, Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. For insulin naive, only ONWARDS 1, 3 and 5 contribute. For basal insulin, only ONWARDS 2 contributes, hence the percentages and rates are unadjusted. For basal-bolus, only ONWARDS 4 contributes, hence the percentages and rates are unadjusted. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): PRINSTR; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD PRINSTR; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:00:25 - faedotgrp/faept5pctgrpinsulindotontt2dsas.png

7.7.81 Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Normal	2080				2071			
Impaired	8				7			
Missing	82				92			
PYE (years)								
Normal	1612.64				1603.16			
Impaired	6.17				5.74			
Missing	62.42				71.68			
Events								
Normal	1273	(61.2)	3794	252.32	1200	(58.0)	3635	247.51
Impaired	3		9		6		29	
Missing	52	(64.7)	182	327.68	57	(62.0)	214	307.68
Serious								
Yes								
Normal	162	(7.8)	239	15.03	158	(7.6)	224	13.41
Impaired	1		1		3		5	
Missing	3	(3.8)	5	9.44	8	(8.8)	9	16.22
No								
Normal	1232	(59.2)	3555	237.29	1162	(56.1)	3411	234.10
Impaired	3		8		6		24	
Missing	52	(64.7)	177	318.25	55	(60.1)	205	291.46
Missing								
Normal	0				0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Severity								
Severe								
Normal	88	(4.2)	116	7.66	82	(4.0)	123	6.98
Impaired	1		1		2		4	
Missing	3	(3.8)	4	7.96	5	(5.8)	6	12.37
Moderate								
Normal	489	(23.5)	887	56.55	454	(21.9)	815	52.15
Impaired	0				3		7	
Missing	23	(28.6)	44	75.37	21	(23.8)	34	60.36
Mild								
Normal	1068	(51.3)	2791	188.11	1016	(49.1)	2697	188.38
Impaired	3		8		6		18	
Missing	42	(52.3)	134	244.35	51	(55.6)	174	234.95
Missing								
Normal	0				0			
Impaired	0				0			
Missing	0				0			
Related to basal insulin								
Probable								
Normal	81	(3.9)	118	8.47	69	(3.3)	122	7.72
Impaired	0				2		2	
Missing	1	(1.2)	2	3.97	5	(4.9)	9	12.39
Possible								
Normal	121	(5.8)	174	12.62	98	(4.7)	162	11.85
Impaired	0				0			
Missing	4	(5.0)	5	9.15	7	(7.9)	16	31.78
Unlikely								
Normal	1222	(58.7)	3490	230.32	1164	(56.2)	3345	227.55
Impaired	3		9		6		27	
Missing	51	(63.8)	175	314.56	56	(60.5)	189	263.51
Missing								
Normal	8	(0.4)	12	0.90	6	(0.3)	6	0.39
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to technical complaint for basal insulin								
Yes								
Normal	11	(0.5)	11	0.92	7	(0.3)	8	0.66
Impaired	0				0			
Missing	0				0			
No								
Normal	1270	(61.0)	3770	250.42	1195	(57.7)	3619	246.29
Impaired	3		9		6		29	
Missing	52	(64.7)	182	327.68	57	(62.0)	214	307.68
NA								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Missing								
Normal	8	(0.4)	12	0.90	7	(0.3)	7	0.47
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
Normal	13	(0.6)	16	1.06	12	(0.6)	14	0.77
Impaired	0				0			
Missing	1	(1.4)	2	4.96	1	(0.9)	1	1.78
Not recovered/not resolved								
Normal	569	(27.4)	1054	68.24	532	(25.7)	959	63.16
Impaired	1		4		4		16	
Missing	19	(23.6)	29	51.59	34	(36.9)	67	101.71
Recovered/resolved with sequelae								
Normal	10	(0.5)	10	0.55	16	(0.8)	18	1.15
Impaired	0				0			
Missing	0				0			
Recovering/resolving								
Normal	93	(4.5)	132	9.14	80	(3.9)	97	6.75
Impaired	1		1		2		3	
Missing	2	(2.1)	3	5.05	10	(11.7)	11	19.23
Recovered/resolved								
Normal	1073	(51.6)	2581	173.28	989	(47.8)	2545	175.59
Impaired	3		4		3		10	
Missing	46	(57.2)	148	266.09	47	(51.7)	135	184.96
Unknown								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.09
Impaired	0				0			
Missing	0				0			
Missing								
Normal	0				0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.82 Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Normal	1799				1786			
Impaired	7				7			
Missing	74				85			
PYE (years)								
Normal	1474.84				1462.55			
Impaired	5.67				5.74			
Missing	58.41				68.17			
Events								
Normal	1092	(60.7)	3315	237.27	1017	(57.0)	3045	220.34
Impaired	3		9		6		29	
Missing	44	(61.3)	154	291.77	50	(58.3)	185	257.27
Serious								
Yes								
Normal	151	(8.4)	224	15.68	152	(8.5)	217	14.74
Impaired	1		1		3		5	
Missing	3	(4.2)	5	10.35	7	(8.3)	7	12.25
No								
Normal	1055	(58.6)	3091	221.59	982	(55.0)	2828	205.60
Impaired	3		8		6		24	
Missing	44	(61.3)	149	281.42	48	(56.2)	178	245.02
Missing								
Normal	0				0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Severity								
Severe								
Normal	79	(4.4)	106	7.73	79	(4.4)	120	7.75
Impaired	1		1		2		4	
Missing	3	(4.2)	4	8.74	4	(5.0)	4	8.04
Moderate								
Normal	442	(24.5)	806	56.19	407	(22.8)	737	51.62
Impaired	0				3		7	
Missing	19	(26.5)	35	60.92	17	(20.5)	23	35.76
Mild								
Normal	905	(50.3)	2403	173.35	853	(47.8)	2188	160.97
Impaired	3		8		6		18	
Missing	36	(50.1)	115	222.12	44	(51.3)	158	213.48
Missing								
Normal	0				0			
Impaired	0				0			
Missing	0				0			
Related to basal insulin								
Probable								
Normal	64	(3.6)	98	7.52	62	(3.5)	114	8.04
Impaired	0				2		2	
Missing	1	(1.3)	2	4.36	5	(5.4)	9	13.59
Possible								
Normal	99	(5.5)	148	11.63	82	(4.6)	123	9.34
Impaired	0				0			
Missing	4	(5.4)	5	10.04	6	(7.3)	14	29.33
Unlikely								
Normal	1052	(58.4)	3057	217.08	982	(55.0)	2802	202.51
Impaired	3		9		6		27	
Missing	43	(60.3)	147	277.37	49	(56.7)	162	214.35
Missing								
Normal	8	(0.4)	12	1.04	6	(0.3)	6	0.45
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to technical complaint for basal insulin								
Yes								
Normal	11	(0.6)	11	1.06	7	(0.4)	8	0.77
Impaired	0				0			
Missing	0				0			
No								
Normal	1089	(60.5)	3291	235.07	1012	(56.7)	3029	218.92
Impaired	3		9		6		29	
Missing	44	(61.3)	154	291.77	50	(58.3)	185	257.27
NA								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Missing								
Normal	8	(0.4)	12	1.04	7	(0.4)	7	0.55
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
Normal	12	(0.7)	15	1.12	12	(0.7)	14	0.89
Impaired	0				0			
Missing	1	(1.6)	2	5.44	1	(1.0)	1	1.95
Not recovered/not resolved								
Normal	488	(27.1)	926	64.34	453	(25.4)	828	58.42
Impaired	1		4		4		16	
Missing	14	(19.8)	23	42.09	30	(34.9)	54	75.60
Recovered/resolved with sequelae								
Normal	10	(0.6)	10	0.63	13	(0.7)	15	1.00
Impaired	0				0			
Missing	0				0			
Recovering/resolving								
Normal	87	(4.8)	126	9.90	75	(4.2)	89	6.92
Impaired	1		1		2		3	
Missing	2	(2.3)	3	5.54	10	(12.8)	11	21.10
Recovered/resolved								
Normal	920	(51.1)	2237	161.22	835	(46.8)	2097	153.01
Impaired	3		4		3		10	
Missing	39	(54.3)	126	238.71	40	(47.0)	119	158.63
Unknown								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Missing								
Normal	0				0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.83 Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Normal	2080				2071			
Impaired	8				7			
Missing	82				92			
PYE (years)								
Normal	1612.64				1603.16			
Impaired	6.17				5.74			
Missing	62.42				71.68			
Events								
Normal	1273	(61.2)	3794	252.32	1200	(58.0)	3635	247.51
Impaired	3		9		6		29	
Missing	52	(64.7)	182	327.68	57	(62.0)	214	307.68
Infections and infestations								
All								
Normal	617	(29.7)	869	59.49	589	(28.5)	857	57.57
Impaired	1		2		4		4	
Missing	30	(37.7)	49	85.59	31	(33.1)	44	65.75
COVID-19								
Normal	168	(8.1)	172	11.73	183	(8.8)	190	12.30
Impaired	0				2		2	
Missing	13	(17.0)	13	20.28	7	(7.7)	7	10.43
Nasopharyngitis								
Normal	109	(5.2)	128	9.45	108	(5.2)	128	9.65
Impaired	0				0			
Missing	8	(9.6)	13	25.17	7	(7.1)	7	9.65
Upper respiratory tract infection								
Normal	64	(3.1)	77	4.83	47	(2.3)	50	3.28
Impaired	1		1		1		1	
Missing	3	(4.1)	3	4.14	4	(4.0)	5	7.81
Urinary tract infection								
Normal	42	(2.0)	45	3.09	46	(2.2)	52	3.27
Impaired	0				0			
Missing	1	(1.1)	1	2.21	4	(4.4)	4	6.89
Gastroenteritis								
Normal	31	(1.5)	32	2.48	18	(0.9)	19	1.40
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bronchitis								
Normal	30	(1.4)	31	2.15	19	(0.9)	19	1.25
Impaired	0				0			
Missing	0				0			
Influenza								
Normal	28	(1.4)	31	2.37	31	(1.5)	34	2.65
Impaired	0				0			
Missing	1	(1.2)	1	1.99	2	(2.6)	2	4.46
Pharyngitis								
Normal	20	(1.0)	22	1.40	17	(0.8)	20	1.27
Impaired	0				0			
Missing	1	(1.1)	1	2.21	1	(1.5)	1	2.46
Sinusitis								
Normal	19	(0.9)	21	1.47	17	(0.8)	20	1.22
Impaired	0				0			
Missing	0				2	(2.7)	2	4.98
Cystitis								
Normal	15	(0.7)	16	1.13	17	(0.8)	19	1.22
Impaired	0				0			
Missing	0				0			
COVID-19 pneumonia								
Normal	15	(0.7)	15	0.98	11	(0.5)	11	0.68
Impaired	0				0			
Missing	0				0			
Pneumonia								
Normal	13	(0.6)	13	0.84	6	(0.3)	6	0.39
Impaired	1		1		0			
Missing	1	(0.9)	1	1.53	0			
Conjunctivitis								
Normal	12	(0.6)	12	0.85	7	(0.3)	7	0.44
Impaired	0				0			
Missing	0				0			
Respiratory tract infection viral								
Normal	11	(0.5)	12	0.99	10	(0.5)	11	0.88
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Herpes zoster								
Normal	10	(0.5)	10	0.60	17	(0.8)	18	1.10
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Respiratory tract infection								
Normal	9	(0.4)	9	0.59	5	(0.2)	5	0.32
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Tooth abscess								
Normal	9	(0.4)	9	0.68	7	(0.3)	8	0.49
Impaired	0				0			
Missing	0				0			
Tooth infection								
Normal	8	(0.4)	9	0.55	8	(0.4)	8	0.59
Impaired	0				0			
Missing	1	(1.4)	2	4.96	0			
Rhinitis								
Normal	8	(0.4)	8	0.49	11	(0.5)	14	1.10
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			
Viral infection								
Normal	7	(0.3)	7	0.46	13	(0.6)	16	0.99
Impaired	0				0			
Missing	0				0			
Fungal infection								
Normal	7	(0.3)	8	0.52	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Otitis media								
Normal	6	(0.3)	6	0.46	5	(0.2)	5	0.36
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Gastroenteritis viral								
Normal	6	(0.3)	6	0.38	6	(0.3)	6	0.42
Impaired	0				0			
Missing	0				0			
Lower respiratory tract infection								
Normal	6	(0.3)	6	0.34	3	(0.1)	5	0.30
Impaired	0				0			
Missing	0				0			
Vaginal infection								
Normal	5	(0.2)	6	0.46	3	(0.1)	3	0.18
Impaired	0				0			
Missing	1	(1.4)	1	2.48	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Periodontitis								
Normal	4	(0.2)	4	0.32	7	(0.3)	7	0.49
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Acute sinusitis								
Normal	4	(0.2)	4	0.19	6	(0.3)	6	0.47
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			
Cellulitis								
Normal	4	(0.2)	4	0.22	7	(0.3)	8	0.52
Impaired	0				0			
Missing	0				1	(1.2)	1	2.00
Coronavirus infection								
Normal	4	(0.2)	4	0.19	5	(0.2)	7	0.46
Impaired	0				0			
Missing	0				0			
Ear infection								
Normal	4	(0.2)	4	0.22	5	(0.2)	5	0.31
Impaired	0				0			
Missing	0				0			
Gastrointestinal infection								
Normal	3	(0.1)	3	0.26	5	(0.2)	7	0.48
Impaired	0				0			
Missing	0				0			
Genital infection								
Normal	3	(0.1)	3	0.18	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Respiratory syncytial virus infection								
Normal	3	(0.1)	3	0.18	0			
Impaired	0				0			
Missing	0				0			
Fungal skin infection								
Normal	3	(0.1)	3	0.23	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Wound infection								
Normal	3	(0.1)	3	0.21	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Erysipelas								
Normal	3	(0.1)	3	0.18	2	(0.1)	3	0.21
Impaired	0				0			
Missing	0				0			
Localised infection								
Normal	3	(0.1)	3	0.18	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				1	(1.3)	1	2.52
Tonsillitis								
Normal	3	(0.1)	3	0.23	2	(0.1)	2	0.13
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Gingivitis								
Normal	3	(0.1)	4	0.24	5	(0.2)	5	0.40
Impaired	0				0			
Missing	0				0			
Hordeolum								
Normal	3	(0.1)	3	0.20	4	(0.2)	4	0.31
Impaired	0				0			
Missing	0				0			
Laryngitis								
Normal	3	(0.1)	3	0.14	5	(0.2)	5	0.36
Impaired	0				0			
Missing	0				0			
Vulvovaginal candidiasis								
Normal	3	(0.1)	4	0.22	3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Oral herpes								
Normal	2	(0.1)	3	0.25	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Sepsis								
Normal	2	(0.1)	2	0.17	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Tinea pedis								
Normal	2	(0.1)	2	0.18	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				1	(0.9)	1	1.78

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Paronychia								
Normal	2	(0.1)	2	0.13	2	(0.1)	3	0.25
Impaired	0				0			
Missing	0				0			
Tinea cruris								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Abscess								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Osteomyelitis								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Vulvovaginal mycotic infection								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Abscess limb								
Normal	2	(0.1)	2	0.18	2	(0.1)	3	0.28
Impaired	0				0			
Missing	0				0			
Vulvitis								
Normal	2	(0.1)	2	0.18	0			
Impaired	0				0			
Missing	0				0			
Acarodermatitis								
Normal	2	(0.1)	2	0.09	4	(0.2)	4	0.19
Impaired	0				0			
Missing	0				0			
Genital infection fungal								
Normal	2	(0.1)	3	0.25	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Furuncle								
Normal	2	(0.1)	3	0.18	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin infection								
Normal	2	(0.1)	2	0.13	3	(0.1)	3	0.28
Impaired	0				0			
Missing	0				0			
Tinea infection								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Helicobacter infection								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Subcutaneous abscess								
Normal	2	(0.1)	2	0.13	2	(0.1)	3	0.15
Impaired	0				0			
Missing	0				0			
Onychomycosis								
Normal	2	(0.1)	2	0.13	3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				1	(1.2)	1	1.31
Candida infection								
Normal	2	(0.1)	2	0.10	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Cholecystitis infective								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Diabetic foot infection								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Infected dermal cyst								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Pharyngotonsillitis								
Normal	1	(0.0)	1	0.08	2	(0.1)	3	0.15
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pneumonia viral								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Pulmonary tuberculoma								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Viral tracheitis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Breast abscess								
Normal	1	(0.0)	1	0.10	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Eye infection								
Normal	1	(0.0)	1	0.10	3	(0.1)	3	0.25
Impaired	0				0			
Missing	0				0			
Norovirus infection								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Severe acute respiratory syndrome								
Normal	1	(0.0)	1	0.10	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Vulvovaginitis								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Escherichia bacteraemia								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Injection site abscess								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oral candidiasis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Postoperative wound infection								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Suspected COVID-19								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Appendicitis								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Chronic sinusitis								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Clostridium difficile colitis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Clostridium difficile infection								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Ear infection fungal								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Gangrene								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Nail infection								
Normal	1	(0.0)	2	0.09	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Otitis externa								
Normal	1	(0.0)	1	0.05	6	(0.3)	6	0.43
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			
Peritonsillar abscess								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Post-acute COVID-19 syndrome								
Normal	1	(0.0)	2	0.09	0			
Impaired	0				0			
Missing	0				0			
Pyelonephritis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Skin candida								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Anal abscess								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Enteritis infectious								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Kidney infection								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Paraspinal abscess								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Pulpitis dental								
Normal	1	(0.0)	1	0.08	4	(0.2)	4	0.30
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pustule								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Tinea versicolour								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Varicella zoster virus infection								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Asymptomatic COVID-19								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Bacterial infection								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Balanitis candida								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Chlamydial infection								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Chronic tonsillitis								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Dermatophytosis of nail								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Escherichia urinary tract infection								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Folliculitis								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Helicobacter gastritis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Herpes simplex								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Herpes virus infection								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Infected bite								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Laryngopharyngitis								
Normal	1	(0.0)	1	0.05	1	(0.0)	2	0.09
Impaired	0				0			
Missing	0				0			
Mastitis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Oropharyngeal candidiasis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Otitis media chronic								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Purulence								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tracheitis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Urethritis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Viral upper respiratory tract infection								
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				0			
Abdominal abscess								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Bacteraemia								
Normal	0				0			
Impaired	0				0			
Missing	1	(0.9)	1	1.53	0			
Bartholinitis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Body tinea								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Breast cellulitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Campylobacter gastroenteritis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Chronic hepatitis C								
Normal	0				0			
Impaired	0				1		1	
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cystitis escherichia								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Diverticulitis								
Normal	0				3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				2	(1.8)	2	1.84
Empyema								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Endophthalmitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Epididymitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Eye infection bacterial								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Fungal balanitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Gastric infection								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Gastroenteritis norovirus								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Genital candidiasis								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Giardiasis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Herpes dermatitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Herpes zoster infection neurological								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Infected cyst								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Infective iritis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Labyrinthitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Lyme disease								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Oophoritis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Otitis media acute								
Normal	0				3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Parotitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Peri-implantitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Pericoronitis								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Post procedural infection								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Rotavirus infection								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Salpingitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Sinusitis bacterial								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Skin bacterial infection								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Soft tissue infection								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Sweat gland infection								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Urosepsis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				1	(1.2)	1	1.31

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Varicella								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Viral pharyngitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Viral rhinitis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Gastrointestinal disorders								
All								
Normal	260	(12.5)	392	25.17	231	(11.2)	322	21.86
Impaired	1		1		2		2	
Missing	16	(20.6)	25	44.16	12	(11.7)	19	23.56
Diarrhoea								
Normal	83	(4.0)	101	6.42	48	(2.3)	50	3.49
Impaired	0				1		1	
Missing	6	(7.3)	7	12.21	6	(5.9)	6	7.13
Nausea								
Normal	36	(1.7)	37	2.35	32	(1.5)	33	2.34
Impaired	0				0			
Missing	5	(6.1)	5	8.66	3	(3.4)	4	5.68
Vomiting								
Normal	30	(1.4)	38	2.82	19	(0.9)	22	1.47
Impaired	0				0			
Missing	1	(1.1)	1	2.21	2	(2.2)	2	3.45
Abdominal pain								
Normal	16	(0.8)	16	0.99	17	(0.8)	18	1.18
Impaired	0				0			
Missing	1	(1.4)	1	2.48	1	(0.9)	1	0.92
Constipation								
Normal	16	(0.8)	19	1.26	15	(0.7)	15	1.04
Impaired	0				0			
Missing	1	(1.4)	1	2.48	1	(0.9)	1	0.92
Abdominal pain upper								
Normal	14	(0.7)	16	1.12	15	(0.7)	15	0.94
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	2	(2.3)	2	2.38	1	(0.9)	2	1.84
Gastrooesophageal reflux disease								
Normal	14	(0.7)	14	0.86	15	(0.7)	15	0.99
Impaired	0				0			
Missing	0				0			
Toothache								
Normal	14	(0.7)	14	0.84	13	(0.6)	18	1.50
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Dental caries								
Normal	12	(0.6)	14	0.72	10	(0.5)	10	0.69
Impaired	0				0			
Missing	0				0			
Chronic gastritis								
Normal	9	(0.4)	9	0.62	6	(0.3)	6	0.43
Impaired	0				0			
Missing	0				0			
Gastritis								
Normal	8	(0.4)	8	0.57	9	(0.4)	9	0.56
Impaired	0				0			
Missing	0				0			
Dyspepsia								
Normal	8	(0.4)	8	0.56	9	(0.4)	9	0.58
Impaired	0				0			
Missing	0				0			
Abdominal distension								
Normal	8	(0.4)	8	0.47	5	(0.2)	5	0.36
Impaired	0				0			
Missing	0				0			
Haemorrhoids								
Normal	7	(0.3)	7	0.40	4	(0.2)	4	0.31
Impaired	0				0			
Missing	0				0			
Food poisoning								
Normal	5	(0.2)	5	0.30	4	(0.2)	5	0.38
Impaired	0				0			
Missing	0				0			
Abdominal discomfort								
Normal	4	(0.2)	4	0.28	6	(0.3)	7	0.49
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Diverticulum intestinal								
Normal	4	(0.2)	4	0.24	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Large intestine polyp								
Normal	4	(0.2)	4	0.22	6	(0.3)	7	0.37
Impaired	0				0			
Missing	0				0			
Abdominal pain lower								
Normal	4	(0.2)	4	0.26	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Hypoaesthesia oral								
Normal	3	(0.1)	5	0.39	0			
Impaired	0				0			
Missing	0				0			
Flatulence								
Normal	3	(0.1)	3	0.18	2	(0.1)	2	0.17
Impaired	0				0			
Missing	1	(1.4)	1	2.48	0			
Enterocolitis								
Normal	3	(0.1)	4	0.19	0			
Impaired	0				0			
Missing	0				0			
Pancreatic failure								
Normal	2	(0.1)	2	0.18	0			
Impaired	0				0			
Missing	0				0			
Anal fissure								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Impaired gastric emptying								
Normal	2	(0.1)	3	0.24	0			
Impaired	0				0			
Missing	0				0			
Aphthous ulcer								
Normal	2	(0.1)	2	0.09	0			
Impaired	0				0			
Missing	0				0			
Inguinal hernia								
Normal	2	(0.1)	2	0.09	1	(0.0)	2	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Gastric polyps								
Normal	2	(0.1)	2	0.13	4	(0.2)	4	0.33
Impaired	0				0			
Missing	0				0			
Hiatus hernia								
Normal	2	(0.1)	2	0.13	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Dry mouth								
Normal	2	(0.1)	2	0.09	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Rectal polyp								
Normal	2	(0.1)	2	0.09	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Hyperaesthesia teeth								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Pancreatitis chronic								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Proctalgia								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Faeces soft								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Irritable bowel syndrome								
Normal	1	(0.0)	1	0.10	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Gastric dilatation								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oral pain								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Vomiting projectile								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Abdominal wall disorder								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Colitis microscopic								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Diabetic gastropathy								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Eosinophilic oesophagitis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Gastric ulcer								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Gastrointestinal haemorrhage								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Intestinal dilatation								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Lip swelling								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Umbilical hernia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Diverticulum								
Normal	1	(0.0)	1	0.08	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Gastrointestinal angiodysplasia								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Gingival bleeding								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Intra-abdominal haematoma								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Colitis								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Colitis ischaemic								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Frequent bowel movements								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Haematochezia								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Loose tooth								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Oral discomfort								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Pancreatitis								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Tooth disorder								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Tooth impacted								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Acid peptic disease								
Normal	0				2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Anal pruritus								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Crohn's disease								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Duodenitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Enteritis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Epigastric discomfort								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Eructation								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Faeces pale								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Gastric disorder								
Normal	0				0			
Impaired	0				1		1	
Missing	0				0			
Gastric dysplasia								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	1.78
Gastric mucosal hypertrophy								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Gastritis erosive								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Gastrointestinal disorder								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Gastrointestinal inflammation								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Gastrointestinal sounds abnormal								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Gingival disorder								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Gingival recession								
Normal	0				1	(0.0)	2	0.19
Impaired	0				0			
Missing	0				0			
Haemorrhoidal haemorrhage								
Normal	0				1	(0.0)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Hyperchlorhydria								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Ileus								
Normal	0				2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Lumbar hernia								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Melaena								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Mesenteric panniculitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Noninfective gingivitis								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			
Odynophagia								
Normal	0				2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				0			
Oesophageal pain								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Oesophagitis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Pancreatic duct dilatation								
Normal	0				0			
Impaired	1		1		0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pancreatic pseudocyst								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Pancreatitis acute								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Peptic ulcer								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Periodontal disease								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Periodontal inflammation								
Normal	0				1	(0.0)	2	0.10
Impaired	0				0			
Missing	0				0			
Pneumatosis intestinalis								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Rectal prolapse								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Small intestinal obstruction								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Stomatitis								
Normal	0				2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Tongue rough								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.4)	1	2.48	0			
Ulcerative gastritis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Upper gastrointestinal haemorrhage								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Musculoskeletal and connective tissue disorders								
All								
Normal	253	(12.1)	375	23.84	268	(13.0)	375	25.50
Impaired	1		1		2		5	
Missing	19	(25.2)	24	44.12	14	(14.4)	21	29.73
Back pain								
Normal	60	(2.9)	63	4.00	68	(3.3)	84	6.26
Impaired	0				0			
Missing	5	(7.0)	6	10.36	4	(4.0)	5	7.40
Arthralgia								
Normal	43	(2.1)	50	3.24	54	(2.6)	59	4.12
Impaired	0				0			
Missing	8	(10.9)	9	16.73	3	(2.8)	4	4.54
Pain in extremity								
Normal	37	(1.8)	39	2.40	34	(1.6)	40	2.84
Impaired	0				0			
Missing	0				3	(3.4)	3	4.76
Muscle spasms								
Normal	24	(1.1)	26	1.78	7	(0.3)	7	0.41
Impaired	0				1		1	
Missing	1	(1.4)	1	2.48	1	(0.9)	1	0.92
Osteoarthritis								
Normal	22	(1.1)	24	1.45	24	(1.2)	27	1.70
Impaired	0				0			
Missing	2	(2.2)	2	4.41	2	(2.2)	2	3.45
Myalgia								
Normal	16	(0.8)	16	1.14	16	(0.8)	17	1.38
Impaired	0				0			
Missing	0				0			
Neck pain								
Normal	15	(0.7)	15	1.02	8	(0.4)	8	0.46
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Trigger finger								
Normal	8	(0.4)	8	0.63	6	(0.3)	8	0.47
Impaired	0				0			
Missing	1	(0.9)	1	1.53	0			
Intervertebral disc protrusion								
Normal	8	(0.4)	12	0.64	6	(0.3)	7	0.41
Impaired	0				0			
Missing	0				0			
Tendonitis								
Normal	8	(0.4)	10	0.60	5	(0.2)	5	0.36
Impaired	0				0			
Missing	0				0			
Periarthritis								
Normal	8	(0.4)	8	0.45	8	(0.4)	8	0.57
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Spinal osteoarthritis								
Normal	6	(0.3)	6	0.36	4	(0.2)	4	0.19
Impaired	0				1		2	
Missing	0				0			
Arthritis								
Normal	6	(0.3)	6	0.40	6	(0.3)	6	0.43
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Rotator cuff syndrome								
Normal	5	(0.2)	5	0.31	4	(0.2)	4	0.18
Impaired	0				0			
Missing	0				0			
Musculoskeletal stiffness								
Normal	4	(0.2)	4	0.31	2	(0.1)	2	0.15
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Bursitis								
Normal	4	(0.2)	4	0.22	3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				1	(1.3)	1	2.52
Spinal stenosis								
Normal	4	(0.2)	6	0.42	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Plantar fasciitis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	4	(0.2)	5	0.27	3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Muscular weakness								
Normal	3	(0.1)	3	0.23	3	(0.1)	3	0.21
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			
Foot deformity								
Normal	3	(0.1)	5	0.27	2	(0.1)	2	0.17
Impaired	0				1		1	
Missing	0				0			
Tendon disorder								
Normal	3	(0.1)	3	0.21	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Exostosis								
Normal	3	(0.1)	3	0.14	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Synovial cyst								
Normal	3	(0.1)	3	0.20	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Intervertebral disc disorder								
Normal	3	(0.1)	3	0.18	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Osteochondrosis								
Normal	2	(0.1)	2	0.13	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				1	(1.5)	1	2.46
Joint effusion								
Normal	2	(0.1)	3	0.21	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Back disorder								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Coccydynia								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.05
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Tenosynovitis								
Normal	2	(0.1)	2	0.15	8	(0.4)	9	0.51
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Musculoskeletal pain								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Chondropathy								
Normal	2	(0.1)	2	0.09	0			
Impaired	0				0			
Missing	0				0			
Polyarthritis								
Normal	2	(0.1)	2	0.09	0			
Impaired	0				0			
Missing	0				0			
Osteoporosis								
Normal	2	(0.1)	2	0.16	0			
Impaired	0				0			
Missing	0				0			
Fibromyalgia								
Normal	2	(0.1)	2	0.10	0			
Impaired	0				0			
Missing	0				0			
Groin pain								
Normal	2	(0.1)	2	0.10	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Musculoskeletal chest pain								
Normal	2	(0.1)	2	0.10	2	(0.1)	2	0.10
Impaired	1		1		0			
Missing	0				0			
Limb discomfort								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Arthropathy								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Muscle contracture								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Pain in jaw								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Torticollis								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Acquired claw toe								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Diastasis recti abdominis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Facet joint syndrome								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Meniscopathy								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Psoriatic arthropathy								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Sacroiliitis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Axillary mass								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Polymyalgia rheumatica								
Normal	1	(0.0)	1	0.08	1	(0.0)	3	0.25

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Soft tissue swelling								
Normal	1	(0.0)	3	0.24	0			
Impaired	0				0			
Missing	0				0			
Bone cyst								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Costochondritis								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Fistula								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Lumbar spinal stenosis								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Myositis								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Osteopenia								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Spinal pain								
Normal	1	(0.0)	1	0.05	4	(0.2)	4	0.23
Impaired	0				0			
Missing	0				0			
Bone pain								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Cervical spinal stenosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Chondromalacia								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Dupuytren's contracture								
Normal	0				2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Flank pain								
Normal	0				5	(0.2)	6	0.36
Impaired	0				1		1	
Missing	1	(1.4)	1	2.48	0			
Haemarthrosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Intervertebral disc degeneration								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Intervertebral disc space narrowing								
Normal	0				1	(0.0)	2	0.09
Impaired	0				0			
Missing	0				0			
Jaw disorder								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Joint swelling								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Limb deformity								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Limb mass								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Mastication disorder								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.0)	2	0.10
Impaired	0				0			
Missing	0				0			
Muscle twitching								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Neuropathic arthropathy								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Nodal osteoarthritis								
Normal	0				2	(0.1)	2	0.14
Impaired	0				0			
Missing	0				0			
Osteochondritis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Periostitis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Rheumatoid arthritis								
Normal	0				4	(0.2)	4	0.32
Impaired	0				0			
Missing	0				0			
Scoliosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Spinal retrolisthesis								
Normal	0				1	(0.0)	2	0.09
Impaired	0				0			
Missing	0				0			
Tenosynovitis stenosans								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Vertebral osteophyte								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
General disorders and administration site conditions								
All								
Normal	227	(10.9)	343	24.03	194	(9.4)	318	21.98
Impaired	0				0			
Missing	13	(15.7)	20	33.69	14	(14.1)	26	41.95
Pyrexia								
Normal	38	(1.8)	40	2.73	38	(1.8)	40	2.76
Impaired	0				0			
Missing	3	(3.3)	3	5.54	5	(4.6)	5	4.61
Fatigue								
Normal	31	(1.5)	35	2.31	15	(0.7)	15	0.91
Impaired	0				0			
Missing	1	(1.1)	1	2.21	1	(0.9)	1	0.92
Oedema peripheral								
Normal	18	(0.9)	18	1.20	10	(0.5)	11	0.65
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			
Malaise								
Normal	16	(0.8)	18	1.15	14	(0.7)	59	5.18
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Injection site reaction								
Normal	15	(0.7)	29	2.33	6	(0.3)	8	0.48
Impaired	0				0			
Missing	0				0			
Pain								
Normal	12	(0.6)	13	0.97	13	(0.6)	14	0.88
Impaired	0				0			
Missing	1	(1.1)	1	2.21	1	(0.9)	1	0.92
Chest pain								
Normal	12	(0.6)	12	0.75	7	(0.3)	7	0.43
Impaired	0				0			
Missing	2	(2.3)	2	2.38	0			
Asthenia								
Normal	10	(0.5)	10	0.65	9	(0.4)	9	0.64
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Vaccination site pain								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	9	(0.4)	11	0.73	9	(0.4)	9	0.66
Impaired	0				0			
Missing	1	(0.9)	1	1.53	0			
Medical device site reaction								
Normal	7	(0.3)	9	0.69	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Influenza like illness								
Normal	7	(0.3)	8	0.64	4	(0.2)	4	0.24
Impaired	0				0			
Missing	0				0			
Medical device site bruise								
Normal	7	(0.3)	9	0.60	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hunger								
Normal	7	(0.3)	8	0.47	2	(0.1)	3	0.24
Impaired	0				0			
Missing	0				1	(0.9)	1	1.78
Medical device site rash								
Normal	6	(0.3)	6	0.59	7	(0.3)	7	0.67
Impaired	0				0			
Missing	0				1	(1.3)	1	2.52
Medical device site dermatitis								
Normal	6	(0.3)	9	0.62	9	(0.4)	16	0.98
Impaired	0				0			
Missing	1	(0.9)	1	1.53	2	(1.8)	2	1.84
Chest discomfort								
Normal	6	(0.3)	6	0.39	2	(0.1)	2	0.13
Impaired	0				0			
Missing	2	(2.9)	2	3.95	0			
Injection site pruritus								
Normal	4	(0.2)	19	1.50	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Peripheral swelling								
Normal	4	(0.2)	5	0.31	4	(0.2)	4	0.26
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Medical device site pruritus								
Normal	4	(0.2)	4	0.28	4	(0.2)	4	0.34
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	1	(1.5)	1	1.47	0			
Chills								
Normal	4	(0.2)	4	0.22	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Feeling abnormal								
Normal	3	(0.1)	5	0.31	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Injection site pain								
Normal	3	(0.1)	3	0.25	12	(0.6)	30	1.66
Impaired	0				0			
Missing	0				1	(1.2)	1	2.00
Injection site bruising								
Normal	3	(0.1)	3	0.21	5	(0.2)	5	0.27
Impaired	0				0			
Missing	0				0			
Thirst								
Normal	3	(0.1)	3	0.22	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Injection site erythema								
Normal	3	(0.1)	5	0.38	3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Drug intolerance								
Normal	3	(0.1)	3	0.14	0			
Impaired	0				0			
Missing	0				0			
Gait disturbance								
Normal	3	(0.1)	3	0.14	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Inflammation								
Normal	2	(0.1)	2	0.18	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Swelling face								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Injection site haematoma								
Normal	2	(0.1)	6	0.50	2	(0.1)	6	0.50
Impaired	0				0			
Missing	0				1	(1.2)	2	4.00
Injection site haemorrhage								
Normal	2	(0.1)	2	0.17	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Injection site swelling								
Normal	2	(0.1)	2	0.16	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Discomfort								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				1	(1.5)	8	19.66
Injection site mass								
Normal	2	(0.1)	2	0.09	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Medical device site erythema								
Normal	2	(0.1)	2	0.16	5	(0.2)	6	0.52
Impaired	0				0			
Missing	0				0			
Injection site hypersensitivity								
Normal	2	(0.1)	2	0.10	0			
Impaired	0				0			
Missing	0				0			
Medical device site haemorrhage								
Normal	2	(0.1)	2	0.10	3	(0.1)	3	0.20
Impaired	0				0			
Missing	2	(2.9)	2	2.95	0			
Multiple organ dysfunction syndrome								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Oedema								
Normal	1	(0.0)	1	0.08	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Vaccination site inflammation								
Normal	1	(0.0)	1	0.08	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Vaccination site pruritus								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Xerosis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Injection site urticaria								
Normal	1	(0.0)	2	0.20	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Medical device site haematoma								
Normal	1	(0.0)	1	0.10	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Medical device site irritation								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Medical device site pain								
Normal	1	(0.0)	1	0.10	3	(0.1)	3	0.23
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Application site bruise								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Injection site rash								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Early satiety								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Localised oedema								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vessel puncture site bruise								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Feeling hot								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Implant site pruritus								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Medical device site eczema								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Medical device site hypersensitivity								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Swelling								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Vaccination site reaction								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Application site pruritus								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			
Axillary pain								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Condition aggravated								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Cyst								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Death								
Normal	0				3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Facial pain								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Hernia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hyperthermia								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Injection site dermatitis								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Injection site hypertrophy								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Injection site induration								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Injection site oedema								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Medical device site inflammation								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Non-cardiac chest pain								
Normal	0				4	(0.2)	6	0.28
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Oedema due to renal disease								
Normal	0				0			
Impaired	0				0			
Missing	1	(0.9)	1	1.53	0			
Procedural failure								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Systemic inflammatory response syndrome								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Vaccination site erythema								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Nervous system disorders								
All								
Normal	199	(9.6)	285	19.42	194	(9.4)	312	22.69
Impaired	0				1		1	
Missing	8	(10.7)	13	26.50	12	(11.9)	13	15.38
Headache								
Normal	64	(3.1)	82	5.96	59	(2.8)	75	5.27
Impaired	0				0			
Missing	6	(7.8)	10	21.07	5	(4.9)	5	5.85
Dizziness								
Normal	40	(1.9)	51	3.32	37	(1.8)	45	3.12
Impaired	0				0			
Missing	0				2	(1.8)	2	1.84
Sciatica								
Normal	13	(0.6)	13	0.86	10	(0.5)	10	0.62
Impaired	0				0			
Missing	0				2	(1.8)	3	2.76
Tremor								
Normal	12	(0.6)	13	0.74	9	(0.4)	60	5.60
Impaired	0				0			
Missing	0				1	(1.2)	1	2.00
Carpal tunnel syndrome								
Normal	11	(0.5)	11	0.66	8	(0.4)	8	0.58

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Hypoaesthesia								
Normal	9	(0.4)	12	0.75	9	(0.4)	10	0.64
Impaired	0				0			
Missing	0				1	(1.2)	1	2.00
Migraine								
Normal	8	(0.4)	9	0.68	5	(0.2)	5	0.41
Impaired	0				0			
Missing	0				0			
Paraesthesia								
Normal	8	(0.4)	9	0.46	11	(0.5)	11	0.78
Impaired	0				1		1	
Missing	0				0			
Syncope								
Normal	7	(0.3)	7	0.42	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Diabetic neuropathy								
Normal	6	(0.3)	6	0.45	12	(0.6)	12	0.78
Impaired	0				0			
Missing	0				0			
Neuropathy peripheral								
Normal	6	(0.3)	7	0.48	10	(0.5)	10	0.63
Impaired	0				0			
Missing	0				0			
Dysgeusia								
Normal	3	(0.1)	3	0.18	0			
Impaired	0				0			
Missing	0				0			
Transient ischaemic attack								
Normal	3	(0.1)	3	0.18	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Burning sensation								
Normal	3	(0.1)	3	0.20	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Disturbance in attention								
Normal	2	(0.1)	10	0.94	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Amnesia								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Cerebrovascular disorder								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Memory impairment								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Autonomic nervous system imbalance								
Normal	2	(0.1)	2	0.18	0			
Impaired	0				0			
Missing	0				0			
Cervicobrachial syndrome								
Normal	2	(0.1)	2	0.18	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Somnolence								
Normal	2	(0.1)	2	0.18	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Carotid artery stenosis								
Normal	2	(0.1)	2	0.09	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Neuralgia								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Post herpetic neuralgia								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Tension headache								
Normal	2	(0.1)	3	0.14	0			
Impaired	0				0			
Missing	1	(1.4)	1	2.48	0			
Cerebral arteriosclerosis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Vascular encephalopathy								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Haemorrhage intracranial								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Hypoglycaemic seizure								
Normal	1	(0.0)	1	0.10	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Loss of consciousness								
Normal	1	(0.0)	1	0.10	2	(0.1)	2	0.14
Impaired	0				0			
Missing	0				0			
Sinus headache								
Normal	1	(0.0)	1	0.10	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Speech disorder								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Vascular headache								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Cerebral atrophy								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Cluster headache								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Cognitive disorder								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Intracranial pressure increased								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Carotid artery aneurysm								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Facial paralysis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Peripheral paralysis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Piriformis syndrome								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Thalamic infarction								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Balance disorder								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Cerebral haemorrhage								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Cervical radiculopathy								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Dizziness postural								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lumbar radiculopathy								
Normal	1	(0.0)	1	0.05	4	(0.2)	5	0.24
Impaired	0				0			
Missing	0				0			
Neuroglycopenia								
Normal	1	(0.0)	1	0.05	1	(0.0)	3	0.15
Impaired	0				0			
Missing	0				0			
Presyncope								
Normal	1	(0.0)	1	0.05	4	(0.2)	4	0.19
Impaired	0				0			
Missing	0				0			
Trigeminal neuralgia								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Ageusia								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Anosmia								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Basilar migraine								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Brain injury								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Carotid arteriosclerosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Cerebral artery embolism								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Cerebral infarction								
Normal	0				1	(0.0)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Cerebrovascular accident								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Dementia Alzheimer's type								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Encephalopathy								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Essential tremor								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Facial nerve disorder								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Hemiparesis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Hypoglycaemic coma								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Hypoglycaemic unconsciousness								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Hyporeflexia								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Hypotonia								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ischaemic stroke								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Lethargy								
Normal	0				2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Mental impairment								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Meralgia paraesthetica								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Morton's neuralgia								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Myelopathy								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Ophthalmic migraine								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Orthostatic tremor								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Parkinsonian gait								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Radiculopathy								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Restless legs syndrome								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Sleep deficit								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Thrombotic stroke								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Vertebral artery occlusion								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
White matter lesion								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Injury, poisoning and procedural complications								
All								
Normal	187	(9.0)	229	15.51	170	(8.2)	203	14.58
Impaired	0				1		1	
Missing	7	(9.2)	12	24.89	9	(10.1)	13	18.74
Fall								
Normal	20	(1.0)	20	1.20	10	(0.5)	11	0.71
Impaired	0				0			
Missing	0				1	(1.2)	1	1.31
Vaccination complication								
Normal	18	(0.9)	18	1.22	27	(1.3)	36	2.57
Impaired	0				0			
Missing	2	(2.9)	6	14.87	2	(1.8)	2	1.84
Accidental overdose								
Normal	14	(0.7)	15	1.29	4	(0.2)	5	0.43
Impaired	0				0			
Missing	0				0			
Contusion								
Normal	14	(0.7)	15	0.94	8	(0.4)	8	0.52
Impaired	0				0			
Missing	1	(1.5)	1	1.47	1	(0.9)	1	0.92

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ligament sprain								
Normal	11	(0.5)	11	0.80	8	(0.4)	8	0.56
Impaired	0				0			
Missing	1	(1.1)	1	2.21	0			
Skin abrasion								
Normal	9	(0.4)	12	0.81	5	(0.2)	5	0.39
Impaired	0				0			
Missing	0				0			
Hand fracture								
Normal	7	(0.3)	7	0.49	0			
Impaired	0				0			
Missing	0				1	(1.2)	1	1.31
Skin laceration								
Normal	7	(0.3)	7	0.44	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Incorrect dose administered								
Normal	6	(0.3)	6	0.55	5	(0.2)	7	0.54
Impaired	0				0			
Missing	0				0			
Limb injury								
Normal	6	(0.3)	6	0.41	6	(0.3)	7	0.51
Impaired	0				0			
Missing	0				0			
Prescribed overdose								
Normal	5	(0.2)	5	0.49	0			
Impaired	0				0			
Missing	0				0			
Procedural pain								
Normal	5	(0.2)	5	0.36	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Road traffic accident								
Normal	5	(0.2)	6	0.45	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Joint injury								
Normal	5	(0.2)	5	0.34	5	(0.2)	5	0.32
Impaired	0				0			
Missing	0				0			
Rib fracture								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	4	(0.2)	4	0.26	5	(0.2)	5	0.31
Impaired	0				0			
Missing	0				0			
Foot fracture								
Normal	3	(0.1)	3	0.22	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Arthropod bite								
Normal	3	(0.1)	3	0.25	4	(0.2)	4	0.31
Impaired	0				0			
Missing	0				0			
Tooth fracture								
Normal	3	(0.1)	3	0.22	3	(0.1)	3	0.23
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Arthropod sting								
Normal	3	(0.1)	3	0.18	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Upper limb fracture								
Normal	3	(0.1)	3	0.14	0			
Impaired	0				0			
Missing	0				0			
Overdose								
Normal	3	(0.1)	3	0.21	3	(0.1)	3	0.22
Impaired	0				0			
Missing	1	(1.4)	1	2.48	0			
Wound								
Normal	3	(0.1)	3	0.18	6	(0.3)	6	0.48
Impaired	0				0			
Missing	0				0			
Ankle fracture								
Normal	3	(0.1)	3	0.14	2	(0.1)	2	0.09
Impaired	0				1		1	
Missing	1	(1.2)	1	1.19	0			
Thermal burn								
Normal	3	(0.1)	3	0.21	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Medication error								
Normal	2	(0.1)	2	0.17	3	(0.1)	3	0.26
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Tendon rupture								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Face injury								
Normal	2	(0.1)	2	0.18	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Back injury								
Normal	2	(0.1)	2	0.09	2	(0.1)	2	0.14
Impaired	0				0			
Missing	0				0			
Hip fracture								
Normal	2	(0.1)	2	0.09	0			
Impaired	0				0			
Missing	0				0			
Radius fracture								
Normal	2	(0.1)	2	0.09	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Fibula fracture								
Normal	2	(0.1)	2	0.10	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Injury								
Normal	2	(0.1)	2	0.10	0			
Impaired	0				0			
Missing	0				0			
Meniscus injury								
Normal	2	(0.1)	2	0.10	5	(0.2)	5	0.27
Impaired	0				0			
Missing	0				0			
Accidental underdose								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Chillblains								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Extra dose administered								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Subdural haematoma								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Wrong product administered								
Normal	1	(0.0)	2	0.17	6	(0.3)	6	0.55
Impaired	0				0			
Missing	0				0			
Epicondylitis								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				1	(1.2)	1	1.31
Product administration error								
Normal	1	(0.0)	1	0.10	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Product dispensing error								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Gun shot wound								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Ligament rupture								
Normal	1	(0.0)	2	0.17	0			
Impaired	0				0			
Missing	0				0			
Procedural complication								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Animal bite								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				1	(1.5)	1	2.46
Bone contusion								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.13

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Femoral neck fracture								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Inflammation of wound								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Injury of conjunctiva								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Multiple injuries								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Muscle injury								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Neck injury								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Penile contusion								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post procedural complication								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post procedural haematuria								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post procedural inflammation								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Radiation skin injury								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Spinal compression fracture								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Craniocerebral injury								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Facial bones fracture								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Subcutaneous haematoma								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Underdose								
Normal	1	(0.0)	1	0.08	5	(0.2)	5	0.38
Impaired	0				0			
Missing	0				0			
Wrist fracture								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Burn oral cavity								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Burns first degree								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Cervical vertebral fracture								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Eye injury								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Heat illness								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				2	(1.8)	3	2.76
Muscle strain								
Normal	1	(0.0)	1	0.05	5	(0.2)	5	0.36
Impaired	0				0			
Missing	0				0			
Post procedural fistula								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post procedural haemorrhage								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post procedural hypothyroidism								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Traumatic haematoma								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Anaemia postoperative								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.3)	1	2.52
Animal scratch								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.3)	1	2.52
Clavicle fracture								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Concussion								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Corneal abrasion								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Crush injury								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Deafness traumatic								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Endotracheal intubation complication								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Exposure to SARS-CoV-2								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Head injury								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Heat stroke								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Humerus fracture								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Intentional overdose								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Intentional product use issue								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lower limb fracture								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Muscle contusion								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Nerve injury								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Periprocedural myocardial infarction								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Post procedural stroke								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Post procedural swelling								
Normal	0				1	(0.0)	2	0.10
Impaired	0				0			
Missing	0				0			
Post-traumatic neck syndrome								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Scar								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Scratch								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Seroma								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Soft tissue injury								
Normal	0				2	(0.1)	2	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Spinal column injury								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Stab wound								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	1.78
Sunburn								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Tendon injury								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Tibia fracture								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Wound dehiscence								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Wrong dose								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Eye disorders								
All								
Normal	174	(8.4)	223	15.84	170	(8.2)	223	16.19
Impaired	0				1		1	
Missing	2	(2.4)	2	3.00	9	(9.8)	12	18.97
Diabetic retinopathy								
Normal	63	(3.0)	69	5.29	67	(3.2)	71	5.39
Impaired	0				1		1	
Missing	1	(0.9)	1	1.53	4	(4.3)	4	5.68
Cataract								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	27	(1.3)	32	2.00	25	(1.2)	27	1.70
Impaired	0				0			
Missing	1	(1.5)	1	1.47	2	(2.7)	3	6.23
Macular oedema								
Normal	12	(0.6)	13	1.03	5	(0.2)	5	0.32
Impaired	0				0			
Missing	0				0			
Retinopathy hypertensive								
Normal	8	(0.4)	9	0.67	5	(0.2)	5	0.38
Impaired	0				0			
Missing	0				0			
Dry eye								
Normal	7	(0.3)	7	0.41	6	(0.3)	6	0.38
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Diabetic retinal oedema								
Normal	6	(0.3)	6	0.53	10	(0.5)	11	0.78
Impaired	0				0			
Missing	0				0			
Vision blurred								
Normal	6	(0.3)	6	0.46	5	(0.2)	5	0.31
Impaired	0				0			
Missing	0				0			
Blepharitis								
Normal	5	(0.2)	5	0.27	0			
Impaired	0				0			
Missing	0				0			
Retinal haemorrhage								
Normal	4	(0.2)	4	0.30	0			
Impaired	0				0			
Missing	0				0			
Glaucoma								
Normal	4	(0.2)	4	0.24	6	(0.3)	6	0.47
Impaired	0				0			
Missing	0				0			
Eye pain								
Normal	4	(0.2)	4	0.22	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Non-proliferative retinopathy								
Normal	3	(0.1)	4	0.36	4	(0.2)	4	0.36
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Vitreous detachment								
Normal	3	(0.1)	3	0.18	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Conjunctival haemorrhage								
Normal	3	(0.1)	3	0.23	0			
Impaired	0				0			
Missing	0				0			
Age-related macular degeneration								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Arteriosclerotic retinopathy								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Vitreous haemorrhage								
Normal	2	(0.1)	2	0.17	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Diplopia								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Cataract nuclear								
Normal	2	(0.1)	2	0.18	0			
Impaired	0				0			
Missing	0				0			
Epiretinal membrane								
Normal	2	(0.1)	2	0.18	3	(0.1)	3	0.23
Impaired	0				0			
Missing	0				0			
Posterior capsule opacification								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Ocular hyperaemia								
Normal	2	(0.1)	3	0.25	1	(0.0)	2	0.17
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Conjunctivitis allergic								
Normal	2	(0.1)	3	0.18	0			
Impaired	0				0			
Missing	0				0			
Eye inflammation								
Normal	2	(0.1)	2	0.13	2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Ocular hypertension								
Normal	2	(0.1)	2	0.13	2	(0.1)	3	0.24
Impaired	0				0			
Missing	0				0			
Astigmatism								
Normal	2	(0.1)	3	0.14	5	(0.2)	5	0.36
Impaired	0				0			
Missing	0				0			
Presbyopia								
Normal	1	(0.0)	1	0.08	2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				1	(0.9)	1	1.78
Retinal deposits								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Retinal drusen								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Retinal scar								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Corneal erosion								
Normal	1	(0.0)	1	0.10	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Retinal vascular disorder								
Normal	1	(0.0)	1	0.10	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Amaurosis fugax								
Normal	1	(0.0)	1	0.05	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Angle closure glaucoma								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Conjunctival hyperaemia								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Conjunctival suffusion								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Maculopathy								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Retinal degeneration								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Visual impairment								
Normal	1	(0.0)	1	0.05	2	(0.1)	10	0.80
Impaired	0				0			
Missing	0				0			
Vitreous opacities								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Dry age-related macular degeneration								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Eye irritation								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Lacrimation increased								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Myopia								
Normal	1	(0.0)	1	0.08	3	(0.1)	3	0.19
Impaired	0				0			
Missing	0				0			
Retinal exudates								
Normal	1	(0.0)	1	0.08	2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Retinal vein occlusion								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Acquired epiblepharon								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Asthenopia								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Conjunctival erosion								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Optic disc vascular disorder								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post thrombotic retinopathy								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Retinal aneurysm								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Retinal tear								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Chorioretinal atrophy								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Corneal bleeding								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Cystoid macular oedema								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Dacryoadenitis acquired								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Eye discharge								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Eye pruritus								
Normal	0				1	(0.0)	2	0.17
Impaired	0				0			
Missing	0				0			
Eyelid oedema								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hypermetropia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Macular degeneration								
Normal	0				3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Macular hole								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Meibomianitis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Normal tension glaucoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Ocular ischaemic syndrome								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Open angle glaucoma								
Normal	0				1	(0.0)	2	0.17
Impaired	0				0			
Missing	0				0			
Ophthalmic vein thrombosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Optic disc haemorrhage								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Photophobia								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Photopsia								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Pterygium								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.3)	1	2.52
Retinal artery occlusion								
Normal	0				2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Retinal detachment								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Retinopathy								
Normal	0				2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				0			
Scintillating scotoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Uveitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Visual acuity reduced								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Vitreous degeneration								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Vitreous floaters								
Normal	0				3	(0.1)	3	0.28
Impaired	0				0			
Missing	0				0			
Metabolism and nutrition disorders								
All								
Normal	125	(6.0)	156	9.61	127	(6.1)	157	10.18
Impaired	1		1		2		2	
Missing	6	(7.3)	6	9.05	5	(5.3)	10	11.59
Dyslipidaemia								
Normal	20	(1.0)	21	1.33	17	(0.8)	17	1.21
Impaired	0				0			
Missing	1	(0.9)	1	1.53	0			
Hypoglycaemia								
Normal	18	(0.9)	26	2.06	21	(1.0)	35	2.39
Impaired	0				0			
Missing	0				2	(1.8)	5	4.61
Vitamin D deficiency								
Normal	16	(0.8)	16	0.84	12	(0.6)	12	0.69
Impaired	0				0			
Missing	1	(1.2)	1	1.19	2	(2.5)	2	3.83

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hyperlipidaemia								
Normal	14	(0.7)	14	0.84	13	(0.6)	13	0.76
Impaired	0				0			
Missing	0				0			
Vitamin B12 deficiency								
Normal	10	(0.5)	10	0.46	1	(0.0)	1	0.05
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Hypertriglyceridaemia								
Normal	9	(0.4)	9	0.54	8	(0.4)	8	0.53
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Hyperkalaemia								
Normal	7	(0.3)	8	0.45	10	(0.5)	10	0.66
Impaired	1		1		0			
Missing	0				0			
Hyperglycaemia								
Normal	5	(0.2)	6	0.42	13	(0.6)	13	0.88
Impaired	0				1		1	
Missing	1	(1.4)	1	2.48	0			
Iron deficiency								
Normal	5	(0.2)	5	0.23	3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Hyperuricaemia								
Normal	4	(0.2)	4	0.27	3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Gout								
Normal	4	(0.2)	5	0.24	4	(0.2)	5	0.24
Impaired	0				1		1	
Missing	0				1	(0.9)	1	0.92
Decreased appetite								
Normal	4	(0.2)	4	0.23	5	(0.2)	5	0.27
Impaired	0				0			
Missing	0				0			
Hyponatraemia								
Normal	3	(0.1)	3	0.27	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Hypercholesterolaemia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	3	(0.1)	3	0.22	4	(0.2)	4	0.31
Impaired	0				0			
Missing	0				0			
Increased appetite								
Normal	3	(0.1)	3	0.14	6	(0.3)	7	0.51
Impaired	0				0			
Missing	0				0			
Dehydration								
Normal	2	(0.1)	2	0.13	1	(0.0)	2	0.19
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Fluid retention								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Hypokalaemia								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Diabetes mellitus								
Normal	2	(0.1)	2	0.09	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Zinc deficiency								
Normal	2	(0.1)	2	0.09	0			
Impaired	0				0			
Missing	0				1	(1.2)	1	1.31
Hypoalbuminaemia								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Diabetes mellitus inadequate control								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Folate deficiency								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Hypernatraemia								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Magnesium deficiency								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Malnutrition								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Vitamin B complex deficiency								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Abnormal weight gain								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Obesity								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				0			
Appetite disorder								
Normal	0				1	(0.0)	2	0.10
Impaired	0				0			
Missing	0				0			
Electrolyte imbalance								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Food craving								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Hyperammonaemia								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Hypercalcaemia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Insulin resistance								
Normal	0				2	(0.1)	2	0.14
Impaired	0				0			
Missing	0				0			
Lactic acidosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Lipomatosis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Metabolic acidosis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Metabolic disorder								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Respiratory, thoracic and mediastinal disorders								
All								
Normal	121	(5.8)	162	10.87	118	(5.7)	149	10.36
Impaired	0				1		1	
Missing	11	(14.2)	15	28.95	3	(2.8)	3	2.76
Cough								
Normal	23	(1.1)	25	1.63	28	(1.3)	30	2.13
Impaired	0				0			
Missing	3	(4.0)	4	8.36	0			
Oropharyngeal pain								
Normal	20	(1.0)	22	1.41	16	(0.8)	18	1.33
Impaired	0				0			
Missing	4	(5.3)	4	6.96	3	(2.8)	3	2.76
Rhinorrhoea								
Normal	11	(0.5)	14	1.00	13	(0.6)	13	0.99
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Dyspnoea								
Normal	9	(0.4)	9	0.60	13	(0.6)	14	0.89
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Nasal congestion								
Normal	9	(0.4)	9	0.50	5	(0.2)	5	0.29
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Respiratory disorder								
Normal	8	(0.4)	8	0.70	7	(0.3)	7	0.51
Impaired	0				0			
Missing	0				0			
Sinus congestion								
Normal	6	(0.3)	7	0.51	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Sleep apnoea syndrome								
Normal	6	(0.3)	6	0.32	0			
Impaired	0				0			
Missing	1	(1.4)	1	2.48	0			
Asthma								
Normal	5	(0.2)	6	0.40	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Epistaxis								
Normal	5	(0.2)	9	0.75	2	(0.1)	4	0.27
Impaired	0				0			
Missing	1	(0.9)	1	1.53	0			
Chronic obstructive pulmonary disease								
Normal	4	(0.2)	4	0.29	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Productive cough								
Normal	4	(0.2)	4	0.26	4	(0.2)	4	0.33
Impaired	0				0			
Missing	0				0			
Rhinitis allergic								
Normal	2	(0.1)	2	0.15	6	(0.3)	10	0.68
Impaired	0				0			
Missing	0				0			
Nasal septum deviation								
Normal	2	(0.1)	2	0.17	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Emphysema								
Normal	2	(0.1)	2	0.13	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Pulmonary fibrosis								
Normal	2	(0.1)	3	0.18	0			
Impaired	0				0			
Missing	0				0			
Sinus pain								
Normal	2	(0.1)	3	0.18	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Dyspnoea exertional								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Upper-airway cough syndrome								
Normal	2	(0.1)	2	0.15	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Acute respiratory failure								
Normal	2	(0.1)	2	0.09	1	(0.0)	1	0.05
Impaired	0				0			
Missing	1	(1.4)	1	2.48	0			
Sneezing								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	1	(1.1)	1	2.21	0			
Interstitial lung disease								
Normal	2	(0.1)	2	0.10	0			
Impaired	0				0			
Missing	0				0			
Pleurisy								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Pulmonary hypertension								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Bronchial hyperreactivity								
Normal	1	(0.0)	1	0.10	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Hiccups								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Pulmonary congestion								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Increased viscosity of upper respiratory secretion								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Upper respiratory tract inflammation								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Nasal obstruction								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				1		1	
Missing	0				0			
Respiratory failure								
Normal	1	(0.0)	1	0.08	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Acquired diaphragmatic eventration								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Bronchiectasis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Laryngeal cyst								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Nasal dryness								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Nasal turbinate hypertrophy								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Pulmonary embolism								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Pulmonary mass								
Normal	1	(0.0)	1	0.05	4	(0.2)	4	0.26
Impaired	0				0			
Missing	0				0			
Throat irritation								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				0			
Acute pulmonary oedema								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Allergic bronchitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Allergic cough								
Normal	0				2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				0			
Aphonia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Bronchitis chronic								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Bronchospasm								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	1	(1.2)	1	1.99	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Dry throat								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Dysphonia								
Normal	0				1	(0.0)	2	0.17
Impaired	0				0			
Missing	0				0			
Haemoptysis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Lung disorder								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Paranasal cyst								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Paranasal sinus discomfort								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Pleural disorder								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Pleural effusion								
Normal	0				3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Pleuritic pain								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Respiratory tract inflammation								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

Skin and subcutaneous tissue disorders

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
Normal	119	(5.7)	127	8.46	118	(5.7)	143	9.72
Impaired	1		1		0			
Missing	3	(3.1)	3	5.94	10	(11.1)	12	16.68
Rash								
Normal	14	(0.7)	14	0.99	11	(0.5)	12	0.65
Impaired	0				0			
Missing	0				0			
Eczema								
Normal	9	(0.4)	9	0.50	6	(0.3)	6	0.44
Impaired	0				0			
Missing	1	(0.9)	1	1.53	1	(1.5)	1	2.46
Pruritus								
Normal	8	(0.4)	8	0.48	10	(0.5)	10	0.67
Impaired	0				0			
Missing	0				2	(2.4)	2	3.38
Dermatitis								
Normal	7	(0.3)	7	0.57	7	(0.3)	8	0.54
Impaired	0				0			
Missing	0				0			
Alopecia								
Normal	7	(0.3)	7	0.51	2	(0.1)	2	0.10
Impaired	0				0			
Missing	1	(1.1)	1	2.21	1	(1.2)	1	2.00
Urticaria								
Normal	7	(0.3)	7	0.47	12	(0.6)	12	0.76
Impaired	0				0			
Missing	0				0			
Hyperhidrosis								
Normal	7	(0.3)	7	0.44	4	(0.2)	4	0.26
Impaired	1		1		0			
Missing	0				1	(1.2)	1	1.31
Dermatitis contact								
Normal	7	(0.3)	8	0.49	14	(0.7)	14	1.05
Impaired	0				0			
Missing	0				0			
Skin ulcer								
Normal	4	(0.2)	4	0.26	5	(0.2)	5	0.38
Impaired	0				0			
Missing	0				0			
Cold sweat								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	4	(0.2)	4	0.27	8	(0.4)	12	1.06
Impaired	0				0			
Missing	0				0			
Skin irritation								
Normal	4	(0.2)	5	0.34	3	(0.1)	3	0.19
Impaired	0				0			
Missing	0				0			
Dry skin								
Normal	4	(0.2)	4	0.24	5	(0.2)	5	0.32
Impaired	0				0			
Missing	0				0			
Night sweats								
Normal	3	(0.1)	3	0.18	0			
Impaired	0				0			
Missing	0				0			
Rash erythematous								
Normal	2	(0.1)	2	0.18	0			
Impaired	0				0			
Missing	0				0			
Acne								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Blister								
Normal	2	(0.1)	2	0.18	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Skin lesion								
Normal	2	(0.1)	2	0.15	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Hyperkeratosis								
Normal	2	(0.1)	2	0.13	2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				0			
Dermatitis allergic								
Normal	2	(0.1)	2	0.09	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Ingrowing nail								
Normal	2	(0.1)	2	0.09	1	(0.0)	1	0.05
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				2	(1.8)	2	1.84
Miliaria								
Normal	2	(0.1)	2	0.16	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				2	(1.8)	2	1.84
Psoriasis								
Normal	2	(0.1)	2	0.10	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				1	(1.2)	1	2.00
Intertrigo								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Umbilical haematoma								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Dermal cyst								
Normal	1	(0.0)	1	0.10	3	(0.1)	3	0.23
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Ingrown hair								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Lichen sclerosus								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Macule								
Normal	1	(0.0)	1	0.10	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Xeroderma								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Decubitus ulcer								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ecchymosis								
Normal	1	(0.0)	1	0.08	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Skin odour abnormal								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Diabetic foot								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Erythema								
Normal	1	(0.0)	1	0.05	4	(0.2)	4	0.28
Impaired	0				0			
Missing	0				0			
Livedo reticularis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Nail bed inflammation								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Rash papular								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Angioedema								
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.19
Impaired	0				0			
Missing	0				0			
Granuloma annulare								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Lipodystrophy acquired								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Myxoid cyst								
Normal	1	(0.0)	1	0.05	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Skin exfoliation								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Skin fissures								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Urticaria contact								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Actinic keratosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Alopecia areata								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Asteatosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Chronic spontaneous urticaria								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Cold urticaria								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Dermatitis atopic								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Drug eruption								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Haemorrhage subcutaneous								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hidradenitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	1	(1.1)	1	2.21	0			
Lentigo								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Leukoplakia								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Lipohypertrophy								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Neurodermatitis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Pruritus allergic								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Purpura								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Rash maculo-papular								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Seborrhoea								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Skin discolouration								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Skin reaction								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Telangiectasia								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Urticaria thermal								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Investigations								
All								
Normal	94	(4.5)	109	7.33	74	(3.6)	81	5.55
Impaired	0				1		1	
Missing	0				4	(4.4)	6	10.34
Weight increased								
Normal	20	(1.0)	20	1.29	16	(0.8)	16	1.02
Impaired	0				1		1	
Missing	0				1	(0.9)	1	0.92
Blood creatinine increased								
Normal	8	(0.4)	8	0.58	0			
Impaired	0				0			
Missing	0				0			
SARS-CoV-2 test positive								
Normal	7	(0.3)	7	0.51	4	(0.2)	4	0.39
Impaired	0				0			
Missing	0				0			
Blood pressure increased								
Normal	5	(0.2)	5	0.38	4	(0.2)	4	0.23
Impaired	0				0			
Missing	0				0			
Blood triglycerides increased								
Normal	4	(0.2)	4	0.28	2	(0.1)	2	0.09
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Alanine aminotransferase increased								
Normal	4	(0.2)	4	0.29	0			
Impaired	0				0			
Missing	0				0			
Weight decreased								
Normal	4	(0.2)	4	0.19	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Liver function test increased								
Normal	3	(0.1)	3	0.22	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Blood alkaline phosphatase increased								
Normal	3	(0.1)	3	0.25	0			
Impaired	0				0			
Missing	0				0			
Blood immunoglobulin E increased								
Normal	3	(0.1)	3	0.14	3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Blood cholesterol increased								
Normal	3	(0.1)	3	0.20	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Aspartate aminotransferase increased								
Normal	2	(0.1)	2	0.18	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Electrocardiogram abnormal								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Hepatic enzyme increased								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Low density lipoprotein increased								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Occult blood								
Normal	2	(0.1)	2	0.13	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Prostatic specific antigen increased								
Normal	2	(0.1)	2	0.09	0			
Impaired	0				0			
Missing	0				0			
Catheterisation cardiac								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Eosinophil count increased								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				1	(1.3)	2	5.05
Liver function test abnormal								
Normal	1	(0.0)	1	0.08	1	(0.0)	2	0.17
Impaired	0				0			
Missing	0				0			
Angiogram								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Blood testosterone decreased								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Heart rate increased								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Hepatitis B virus test positive								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Mycobacterium tuberculosis complex test positive								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Occult blood positive								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Arthroscopy								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Blood glucose fluctuation								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Blood potassium increased								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Monocyte count decreased								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Monofilament pressure perception test								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Blood urine present								
Normal	1	(0.0)	3	0.14	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Bone density decreased								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Electrocardiogram ST segment abnormal								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Electrocardiogram T wave inversion								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
QRS axis abnormal								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Thyroid function test abnormal								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Transaminases increased								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Blood creatine increased								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Blood creatine phosphokinase increased								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Body temperature increased								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Glycosylated haemoglobin increased								
Normal	1	(0.0)	1	0.05	2	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
International normalised ratio abnormal								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
International normalised ratio decreased								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
International normalised ratio increased								
Normal	1	(0.0)	2	0.10	0			
Impaired	0				0			
Missing	0				0			
Red blood cell count decreased								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Transferrin saturation decreased								
Normal	1	(0.0)	1	0.05	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Amylase increased								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Antinuclear antibody positive								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Blood glucose decreased								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Blood glucose increased								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Blood pressure decreased								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Blood uric acid increased								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Breath sounds abnormal								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Carbohydrate antigen 19-9 increased								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Cardiac murmur								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				1	(1.3)	1	2.52
Cardiac stress test abnormal								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ejection fraction decreased								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Electrocardiogram P wave biphasic								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Electrocardiogram repolarisation abnormality								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Electrocardiogram ST segment depression								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Free fatty acids increased								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Glomerular filtration rate decreased								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Grip strength decreased								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Haematocrit increased								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Haemoglobin decreased								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Haemoglobin increased								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Intraocular pressure increased								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Lipase increased								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Lipids abnormal								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Lipids increased								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Platelet count decreased								
Normal	0				3	(0.1)	3	0.25
Impaired	0				0			
Missing	0				0			
Vitamin D decreased								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
White blood cell count decreased								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Cardiac disorders								
All								
Normal	92	(4.4)	130	7.54	77	(3.7)	106	6.29
Impaired	0				1		2	
Missing	3	(3.7)	3	4.87	6	(7.0)	7	11.97
Atrial fibrillation								
Normal	13	(0.6)	14	0.75	6	(0.3)	6	0.33
Impaired	0				0			
Missing	0				0			
Coronary artery disease								
Normal	12	(0.6)	12	0.64	8	(0.4)	8	0.41
Impaired	0				1		1	
Missing	0				1	(1.5)	1	2.46

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acute myocardial infarction								
Normal	9	(0.4)	9	0.53	8	(0.4)	8	0.49
Impaired	0				0			
Missing	0				0			
Cardiac failure								
Normal	8	(0.4)	8	0.41	3	(0.1)	4	0.31
Impaired	0				0			
Missing	0				0			
Angina pectoris								
Normal	7	(0.3)	7	0.42	4	(0.2)	4	0.23
Impaired	0				0			
Missing	0				0			
Ventricular extrasystoles								
Normal	7	(0.3)	7	0.49	2	(0.1)	3	0.14
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Palpitations								
Normal	7	(0.3)	7	0.42	7	(0.3)	7	0.47
Impaired	0				0			
Missing	0				0			
Myocardial infarction								
Normal	6	(0.3)	6	0.39	4	(0.2)	4	0.19
Impaired	0				0			
Missing	0				0			
Acute coronary syndrome								
Normal	4	(0.2)	4	0.19	0			
Impaired	0				0			
Missing	0				0			
Cardiac failure congestive								
Normal	4	(0.2)	4	0.22	2	(0.1)	3	0.25
Impaired	0				0			
Missing	0				0			
Myocardial ischaemia								
Normal	3	(0.1)	3	0.22	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				1	(1.3)	1	2.52
Supraventricular extrasystoles								
Normal	3	(0.1)	3	0.21	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Mitral valve incompetence								
Normal	3	(0.1)	3	0.18	2	(0.1)	2	0.09

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Left ventricular hypertrophy								
Normal	3	(0.1)	3	0.14	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Angina unstable								
Normal	3	(0.1)	3	0.14	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				1	(1.3)	1	2.52
Atrioventricular block first degree								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Bundle branch block left								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Arrhythmia								
Normal	2	(0.1)	2	0.09	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Tachycardia								
Normal	2	(0.1)	2	0.09	7	(0.3)	7	0.44
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Bundle branch block right								
Normal	2	(0.1)	2	0.15	7	(0.3)	8	0.50
Impaired	0				0			
Missing	0				0			
Left ventricular dysfunction								
Normal	2	(0.1)	2	0.13	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Supraventricular tachycardia								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Cardiac failure chronic								
Normal	2	(0.1)	2	0.10	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Coronary artery occlusion								
Normal	2	(0.1)	2	0.10	0			
Impaired	0				0			
Missing	0				0			
Aortic valve sclerosis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Left atrial enlargement								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				1	(1.2)	1	1.31
Cardiomegaly								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Cardio-respiratory arrest								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Mitral valve stenosis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Arteriosclerosis coronary artery								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Cardiac flutter								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Aortic valve incompetence								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Atrial flutter								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Atrial thrombosis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Bradycardia								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Cardiac ventricular thrombosis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Chronic coronary syndrome								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Diastolic dysfunction								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Left atrial dilatation								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Pericardial effusion								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Pericarditis								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Sinus tachycardia								
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Tricuspid valve incompetence								
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Aortic valve calcification								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Atrial enlargement								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Atrioventricular block complete								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Cardiac arrest								
Normal	0				2	(0.1)	2	0.09
Impaired	0				0			
Missing	0				0			
Cardiac dysfunction								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Cardiac failure acute								
Normal	0				0			
Impaired	0				1		1	
Missing	0				0			
Cardiac perfusion defect								
Normal	0				1	(0.0)	2	0.17
Impaired	0				0			
Missing	0				0			
Cardiovascular disorder								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.1)	1	2.21	0			
Coronary artery stenosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Sinus arrhythmia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Sinus bradycardia								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				1	(1.2)	1	1.31

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Subendocardial ischaemia								
Normal	0				2	(0.1)	2	0.09
Impaired	0				0			
Missing	0				0			
Ventricular arrhythmia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Ventricular tachycardia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Vascular disorders								
All								
Normal	78	(3.7)	87	5.48	77	(3.7)	94	6.12
Impaired	0				1		3	
Missing	1	(1.5)	1	1.47	2	(2.4)	2	2.62
Hypertension								
Normal	36	(1.7)	36	2.42	36	(1.7)	40	2.70
Impaired	0				1		2	
Missing	1	(1.5)	1	1.47	1	(1.2)	1	1.31
Hypotension								
Normal	6	(0.3)	6	0.36	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Peripheral arterial occlusive disease								
Normal	4	(0.2)	5	0.31	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Arteriosclerosis								
Normal	4	(0.2)	4	0.24	7	(0.3)	7	0.44
Impaired	0				0			
Missing	0				0			
Superficial vein thrombosis								
Normal	3	(0.1)	3	0.14	0			
Impaired	0				0			
Missing	0				0			
Peripheral coldness								
Normal	3	(0.1)	3	0.14	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Orthostatic hypotension								
Normal	2	(0.1)	2	0.17	0			
Impaired	0				0			
Missing	0				0			
Haematoma								
Normal	2	(0.1)	2	0.13	3	(0.1)	3	0.22
Impaired	0				0			
Missing	0				0			
Peripheral artery stenosis								
Normal	2	(0.1)	5	0.35	0			
Impaired	0				0			
Missing	0				0			
Peripheral venous disease								
Normal	2	(0.1)	2	0.13	3	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Blood pressure inadequately controlled								
Normal	2	(0.1)	2	0.09	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Aortic arteriosclerosis								
Normal	2	(0.1)	2	0.10	4	(0.2)	4	0.30
Impaired	0				0			
Missing	0				0			
Deep vein thrombosis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Diabetic vascular disorder								
Normal	1	(0.0)	1	0.08	2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Hypertensive crisis								
Normal	1	(0.0)	1	0.08	2	(0.1)	4	0.30
Impaired	0				0			
Missing	0				0			
Arterial insufficiency								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Varicose ulceration								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Hot flush								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Venous stenosis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Aortic stenosis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				1		1	
Missing	0				0			
Brachiocephalic arteriosclerosis								
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				0			
Flushing								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Hypertensive urgency								
Normal	1	(0.0)	1	0.05	2	(0.1)	3	0.18
Impaired	0				0			
Missing	0				0			
Peripheral artery occlusion								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Peripheral vascular disorder								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Thrombosis								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Varicose vein								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.15
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				1	(1.2)	1	1.31
Aneurysm								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Aortic aneurysm								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Aortic dilatation								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Blood pressure fluctuation								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Iliac artery stenosis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Intermittent claudication								
Normal	0				2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Macroangiopathy								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Neovascularisation								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Peripheral artery aneurysm								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Peripheral ischaemia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Phlebitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Thrombophlebitis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Renal and urinary disorders								
All								
Normal	53	(2.5)	64	4.13	47	(2.3)	63	3.82
Impaired	1		1		1		1	
Missing	0				6	(6.6)	6	8.60
Renal cyst								
Normal	6	(0.3)	6	0.39	5	(0.2)	5	0.32
Impaired	1		1		0			
Missing	0				0			
Pollakiuria								
Normal	5	(0.2)	5	0.38	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Nephrolithiasis								
Normal	5	(0.2)	5	0.24	4	(0.2)	6	0.39
Impaired	0				0			
Missing	0				0			
Chronic kidney disease								
Normal	4	(0.2)	4	0.30	3	(0.1)	3	0.19
Impaired	0				1		1	
Missing	0				2	(2.4)	2	3.38
Dysuria								
Normal	4	(0.2)	5	0.27	3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				1	(1.5)	1	2.46
Renal impairment								
Normal	4	(0.2)	4	0.26	3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				0			
Renal pain								
Normal	3	(0.1)	3	0.24	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acute kidney injury								
Normal	3	(0.1)	3	0.21	5	(0.2)	5	0.23
Impaired	0				0			
Missing	0				0			
Ureterolithiasis								
Normal	3	(0.1)	3	0.18	3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				0			
Diabetic nephropathy								
Normal	3	(0.1)	3	0.18	4	(0.2)	4	0.36
Impaired	0				0			
Missing	0				0			
Microalbuminuria								
Normal	2	(0.1)	2	0.15	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Nocturia								
Normal	2	(0.1)	2	0.09	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Urine odour abnormal								
Normal	2	(0.1)	2	0.13	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Haematuria								
Normal	1	(0.0)	2	0.17	4	(0.2)	4	0.23
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Chromaturia								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Renal failure								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Hypertonic bladder								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Proteinuria								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Urinary incontinence								
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Urinary retention								
Normal	1	(0.0)	1	0.05	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Urinary tract disorder								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Bladder prolapse								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Hydronephrosis								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Nephrotic syndrome								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Polyuria								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Urethral stenosis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Calculus urinary								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Pyelocaliectasis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Renal colic								
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.21
Impaired	0				0			
Missing	0				0			
Bladder mass								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Cystitis haemorrhagic								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hydrocalyx								
Normal	0				2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				0			
Hypertensive nephropathy								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Micturition urgency								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Nephropathy								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Renal mass								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Strangury								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Stress urinary incontinence								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Urinary tract inflammation								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Urinary tract obstruction								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Psychiatric disorders								
All								
Normal	39	(1.9)	42	2.63	38	(1.8)	41	2.84
Impaired	0				1		1	
Missing	2	(2.6)	3	4.86	4	(4.9)	4	8.43
Insomnia								
Normal	11	(0.5)	11	0.71	4	(0.2)	5	0.31
Impaired	0				0			
Missing	0				2	(2.4)	2	3.38
Depression								
Normal	8	(0.4)	8	0.45	10	(0.5)	10	0.72
Impaired	0				1		1	
Missing	0				1	(1.3)	1	2.52
Sleep disorder								
Normal	5	(0.2)	5	0.29	4	(0.2)	4	0.33
Impaired	0				0			
Missing	0				0			
Anxiety								
Normal	5	(0.2)	5	0.33	9	(0.4)	9	0.57
Impaired	0				0			
Missing	1	(1.2)	1	1.19	1	(1.3)	1	2.52
Depressed mood								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Mental status changes								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Attention deficit hyperactivity disorder								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Agitation								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Drug abuse								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Irritability								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	1	(1.2)	1	1.19	0			
Adjustment disorder with mixed anxiety and depressed mood								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Disorientation								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Listless								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post-traumatic stress disorder								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Stress								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Nightmare								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Adjustment disorder								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.4)	1	2.48	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Adjustment disorder with depressed mood								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Affect lability								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Anxiety disorder								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Bruxism								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Drug dependence								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Emotional distress								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Fear								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Major depression								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Mixed anxiety and depressive disorder								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Mood swings								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Persistent depressive disorder								
Normal	0				1	(0.0)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Phobia								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Blood and lymphatic system disorders								
All								
Normal	35	(1.7)	37	2.44	26	(1.3)	26	1.64
Impaired	1		1		2		2	
Missing	0				5	(5.4)	5	7.22
Anaemia								
Normal	20	(1.0)	22	1.48	9	(0.4)	9	0.50
Impaired	0				1		1	
Missing	0				4	(4.5)	4	6.30
Eosinophilia								
Normal	3	(0.1)	3	0.18	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Lymphadenopathy								
Normal	3	(0.1)	3	0.19	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Blood loss anaemia								
Normal	1	(0.0)	1	0.08	2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Lymphadenopathy mediastinal								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Lymphadenitis								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Leukopenia								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Leukocytosis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.14
Impaired	0				0			
Missing	0				0			
Splenomegaly								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Iron deficiency anaemia								
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.23
Impaired	1		1		1		1	
Missing	0				0			
Polycythaemia								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Thrombocytopenia								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Hypochromic anaemia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Normocytic anaemia								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Pancytopenia								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Thrombocytosis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
Normal	33	(1.6)	41	2.61	27	(1.3)	41	2.48
Impaired	0				0			
Missing	2	(2.9)	2	2.95	2	(1.9)	2	2.70

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Eye naevus								
Normal	3	(0.1)	4	0.28	0			
Impaired	0				0			
Missing	0				0			
Colon adenoma								
Normal	3	(0.1)	3	0.21	0			
Impaired	0				0			
Missing	0				0			
Adenocarcinoma pancreas								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Colorectal cancer								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Pancreatic neoplasm								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Haemangioma of liver								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Metastases to liver								
Normal	2	(0.1)	2	0.09	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Seborrhoeic keratosis								
Normal	2	(0.1)	3	0.14	0			
Impaired	0				0			
Missing	0				0			
Osteoma								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Small cell lung cancer								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Benign neoplasm of thyroid gland								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Melanocytic naevus								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Bladder papilloma								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Lung cancer metastatic								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Skin papilloma								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Bladder cancer								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Invasive ductal breast carcinoma								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Invasive lobular breast carcinoma								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Lipoma								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Pancreatic carcinoma								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Renal neoplasm								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Squamous cell carcinoma of skin								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Chronic myeloid leukaemia								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Gastric cancer								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Basal cell carcinoma								
Normal	1	(0.0)	1	0.05	3	(0.1)	3	0.15
Impaired	0				0			
Missing	0				0			
Glioblastoma multiforme								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Oral fibroma								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Prostate cancer								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Salivary gland neoplasm								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Acrochordon								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Adenocarcinoma of colon								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Adrenal adenoma								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Benign renal neoplasm								
Normal	0				2	(0.1)	2	0.14
Impaired	0				0			
Missing	0				0			
Bowen's disease								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Breast cancer								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Breast cancer metastatic								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Colon cancer								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Colon cancer stage II								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Dysplastic naevus								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Endometrial adenocarcinoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Gastrointestinal tract adenoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hepatocellular carcinoma								
Normal	0				1	(0.0)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Invasive breast carcinoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Lung adenocarcinoma								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Lymphangioma								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Malignant melanoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Malignant melanoma in situ								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Malignant peritoneal neoplasm								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Metastases to bone marrow								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Metastases to lymph nodes								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Myxoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Neoplasm skin								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ovarian cancer metastatic								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Pancreatic carcinoma metastatic								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	1.78
Prostatic adenoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Renal cell carcinoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Renal hamartoma								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Small intestine neuroendocrine tumour								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Uterine cancer								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Uterine leiomyoma								
Normal	0				5	(0.2)	5	0.37
Impaired	0				0			
Missing	0				0			
Reproductive system and breast disorders								
All								
Normal	31	(1.5)	31	1.97	24	(1.2)	30	1.93
Impaired	0				0			
Missing	2	(2.6)	2	3.68	3	(2.8)	3	2.76
Benign prostatic hyperplasia								
Normal	6	(0.3)	6	0.41	3	(0.1)	3	0.18
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Erectile dysfunction								
Normal	5	(0.2)	5	0.27	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Intermenstrual bleeding								
Normal	2	(0.1)	2	0.17	0			
Impaired	0				0			
Missing	0				0			
Uterine polyp								
Normal	2	(0.1)	2	0.09	0			
Impaired	0				0			
Missing	0				0			
Dysmenorrhoea								
Normal	1	(0.0)	1	0.10	2	(0.1)	2	0.14
Impaired	0				0			
Missing	0				0			
Prostatomegaly								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Breast pain								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Menstruation delayed								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Prostatic calcification								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Atrophic vulvovaginitis								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Ejaculation failure								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Menstruation irregular								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Pelvic discomfort								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Cervical polyp								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Prostatitis								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Breast mass								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Menopausal symptoms								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Ovarian cyst								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Pruritus genital								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Vulvovaginal pruritus								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Colpocele								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Ectropion of cervix								
Normal	0				1	(0.0)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Fibrocystic breast disease								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Galactorrhoea								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Genital prolapse								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Menopausal disorder								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Ovarian disorder								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Penile pain								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Penile rash								
Normal	0				1	(0.0)	2	0.10
Impaired	0				0			
Missing	0				0			
Premenstrual syndrome								
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	1	(1.1)	1	2.21	0			
Testicular cyst								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Uterine enlargement								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Uterine prolapse								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Vaginal discharge								
Normal	0				2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Vaginal haemorrhage								
Normal	0				2	(0.1)	2	0.09
Impaired	0				0			
Missing	0				0			
Vulvovaginal dryness								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Ear and labyrinth disorders								
All								
Normal	28	(1.3)	31	1.84	23	(1.1)	24	1.58
Impaired	0				0			
Missing	0				1	(1.5)	1	2.46
Vertigo								
Normal	10	(0.5)	11	0.66	8	(0.4)	9	0.56
Impaired	0				0			
Missing	0				1	(1.5)	1	2.46
Ear pain								
Normal	6	(0.3)	6	0.40	2	(0.1)	2	0.18
Impaired	0				0			
Missing	0				0			
Deafness bilateral								
Normal	2	(0.1)	2	0.09	0			
Impaired	0				0			
Missing	0				0			
Vertigo positional								
Normal	2	(0.1)	2	0.09	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hypoacusis								
Normal	2	(0.1)	2	0.13	3	(0.1)	3	0.14
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Tinnitus								
Normal	2	(0.1)	2	0.09	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Cerumen impaction								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Deafness neurosensory								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
External ear pain								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Meniere's disease								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Ear inflammation								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Eustachian tube dysfunction								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Deafness unilateral								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Ear discomfort								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Middle ear inflammation								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Motion sickness								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Presbyacusis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hepatobiliary disorders								
All								
Normal	23	(1.1)	30	1.98	24	(1.2)	28	1.89
Impaired	1		1		1		1	
Missing	0				0			
Hepatic steatosis								
Normal	11	(0.5)	11	0.71	10	(0.5)	10	0.63
Impaired	0				0			
Missing	0				0			
Cholelithiasis								
Normal	3	(0.1)	3	0.14	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hepatomegaly								
Normal	2	(0.1)	2	0.13	0			
Impaired	0				0			
Missing	0				0			
Gallbladder polyp								
Normal	2	(0.1)	2	0.18	3	(0.1)	3	0.28
Impaired	0				0			
Missing	0				0			
Hypertransaminasaemia								
Normal	2	(0.1)	3	0.20	0			
Impaired	0				0			
Missing	0				0			
Cholecystitis chronic								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Hepatic calcification								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cholecystitis								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Hepatic function abnormal								
Normal	1	(0.0)	1	0.08	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Hepatic mass								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Alcoholic liver disease								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Gallbladder cholesterolosis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Liver disorder								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Non-alcoholic steatohepatitis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Bile duct stone								
Normal	0				1	(0.0)	2	0.09
Impaired	0				0			
Missing	0				0			
Biliary colic								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Biliary dyskinesia								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Gallbladder disorder								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.0)	1	0.10
Impaired	0				0			
Missing	0				0			
Hepatic cirrhosis								
Normal	0				1	(0.0)	1	0.08
Impaired	0				1		1	
Missing	0				0			
Hepatic cyst								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hyperplastic cholecystopathy								
Normal	0				0			
Impaired	1		1		0			
Missing	0				0			
Nonalcoholic fatty liver disease								
Normal	0				2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Steatohepatitis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Immune system disorders								
All								
Normal	13	(0.6)	14	0.91	14	(0.7)	15	1.06
Impaired	0				0			
Missing	1	(1.4)	1	2.48	2	(1.9)	2	2.70
Seasonal allergy								
Normal	7	(0.3)	7	0.37	8	(0.4)	8	0.58
Impaired	0				0			
Missing	1	(1.4)	1	2.48	1	(0.9)	1	0.92
Hypersensitivity								
Normal	3	(0.1)	3	0.28	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Drug hypersensitivity								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Food allergy								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Anaphylactic reaction								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Allergy to arthropod bite								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				1	(0.9)	1	1.78
Allergy to arthropod sting								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Immunisation reaction								
Normal	0				1	(0.0)	2	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Congenital, familial and genetic disorders								
All								
Normal	6	(0.3)	6	0.43	5	(0.2)	5	0.27
Impaired	0				0			
Missing	0				0			
Type V hyperlipidaemia								
Normal	3	(0.1)	3	0.21	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Corneal dystrophy								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Cystic fibrosis lung								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Hydrocele								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Atrial septal defect								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Congenital syphilitic osteochondritis								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hypertrophic cardiomyopathy								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Myotonic dystrophy								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Endocrine disorders								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
Normal	6	(0.3)	6	0.36	16	(0.8)	16	1.02
Impaired	0				1		1	
Missing	0				2	(1.8)	2	1.84
Hypothyroidism								
Normal	2	(0.1)	2	0.13	4	(0.2)	4	0.28
Impaired	0				1		1	
Missing	0				0			
Thyroid mass								
Normal	2	(0.1)	2	0.10	2	(0.1)	2	0.13
Impaired	0				0			
Missing	0				0			
Hypogonadism								
Normal	1	(0.0)	1	0.08	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Autoimmune thyroiditis								
Normal	1	(0.0)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Adrenal mass								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Adrenocortical insufficiency acute								
Normal	0				2	(0.1)	2	0.17
Impaired	0				0			
Missing	0				0			
Goitre								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Hyperplasia adrenal								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Hyperprolactinaemia								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hyperthyroidism								
Normal	0				2	(0.1)	2	0.10
Impaired	0				0			
Missing	0				0			
Inappropriate antidiuretic hormone secretion								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Secondary hypogonadism								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Surgical and medical procedures								
All								
Normal	5	(0.2)	5	0.41	5	(0.2)	5	0.31
Impaired	0				0			
Missing	1	(1.5)	1	1.47	1	(0.9)	1	0.92
Shoulder operation								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Tooth extraction								
Normal	1	(0.0)	1	0.08	0			
Impaired	0				0			
Missing	0				0			
Cardiac ablation								
Normal	1	(0.0)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Skin neoplasm excision								
Normal	1	(0.0)	1	0.10	1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Cardiac pacemaker replacement								
Normal	1	(0.0)	1	0.05	1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Knee operation								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.5)	1	1.47	0			
Large intestinal polypectomy								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(0.9)	1	0.92
Removal of foreign body								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Spinal operation								
Normal	0				1	(0.0)	1	0.05
Impaired	0				0			
Missing	0				0			
Toe amputation								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Social circumstances								
All								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			
Menopause								
Normal	0				1	(0.0)	1	0.08
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.84 Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Normal	1799				1786			
Impaired	7				7			
Missing	74				85			
PYE (years)								
Normal	1474.84				1462.55			
Impaired	5.67				5.74			
Missing	58.41				68.17			
Events								
Normal	1092	(60.7)	3315	237.27	1017	(57.0)	3045	220.34
Impaired	3		9		6		29	
Missing	44	(61.3)	154	291.77	50	(58.3)	185	257.27
Infections and infestations								
All								
Normal	519	(28.8)	733	53.30	493	(27.6)	719	51.17
Impaired	1		2		4		4	
Missing	24	(34.1)	38	67.29	26	(29.4)	34	44.45
COVID-19								
Normal	140	(7.8)	143	10.25	153	(8.6)	158	10.64
Impaired	0				2		2	
Missing	12	(17.5)	12	19.83	5	(5.7)	5	5.91
Nasopharyngitis								
Normal	79	(4.4)	94	7.05	74	(4.1)	87	6.57
Impaired	0				0			
Missing	4	(5.7)	5	8.25	5	(5.1)	5	5.05
Upper respiratory tract infection								
Normal	58	(3.2)	71	4.91	41	(2.3)	44	3.12
Impaired	1		1		1		1	
Missing	3	(4.4)	3	4.54	3	(3.0)	3	3.03
Urinary tract infection								
Normal	37	(2.1)	40	3.00	42	(2.4)	46	3.12
Impaired	0				0			
Missing	0				2	(2.0)	2	2.02
Influenza								
Normal	27	(1.5)	30	2.63	26	(1.5)	29	2.50
Impaired	0				0			
Missing	1	(1.3)	1	2.18	2	(2.9)	2	4.89

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bronchitis								
Normal	26	(1.4)	27	2.03	17	(1.0)	17	1.22
Impaired	0				0			
Missing	0				0			
Gastroenteritis								
Normal	25	(1.4)	25	2.07	16	(0.9)	17	1.40
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Pharyngitis								
Normal	16	(0.9)	18	1.17	16	(0.9)	19	1.36
Impaired	0				0			
Missing	0				1	(1.6)	1	2.70
COVID-19 pneumonia								
Normal	14	(0.8)	14	1.02	10	(0.6)	10	0.67
Impaired	0				0			
Missing	0				0			
Sinusitis								
Normal	14	(0.8)	16	1.13	16	(0.9)	19	1.30
Impaired	0				0			
Missing	0				1	(1.6)	1	2.70
Cystitis								
Normal	12	(0.7)	13	0.97	16	(0.9)	18	1.30
Impaired	0				0			
Missing	0				0			
Pneumonia								
Normal	12	(0.7)	12	0.86	6	(0.3)	6	0.45
Impaired	1		1		0			
Missing	1	(1.0)	1	1.68	0			
Herpes zoster								
Normal	9	(0.5)	9	0.58	15	(0.8)	16	1.05
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Respiratory tract infection viral								
Normal	8	(0.4)	9	0.80	8	(0.4)	9	0.79
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Respiratory tract infection								
Normal	8	(0.4)	8	0.57	5	(0.3)	5	0.36
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Conjunctivitis								
Normal	8	(0.4)	8	0.52	7	(0.4)	7	0.51
Impaired	0				0			
Missing	0				0			
Tooth infection								
Normal	7	(0.4)	8	0.52	8	(0.4)	8	0.69
Impaired	0				0			
Missing	1	(1.6)	2	5.44	0			
Tooth abscess								
Normal	7	(0.4)	7	0.55	7	(0.4)	8	0.57
Impaired	0				0			
Missing	0				0			
Fungal infection								
Normal	7	(0.4)	8	0.60	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Viral infection								
Normal	6	(0.3)	6	0.41	9	(0.5)	12	0.70
Impaired	0				0			
Missing	0				0			
Otitis media								
Normal	6	(0.3)	6	0.53	4	(0.2)	4	0.30
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Rhinitis								
Normal	6	(0.3)	6	0.33	7	(0.4)	9	0.71
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Gastroenteritis viral								
Normal	5	(0.3)	5	0.32	4	(0.2)	4	0.26
Impaired	0				0			
Missing	0				0			
Lower respiratory tract infection								
Normal	5	(0.3)	5	0.28	2	(0.1)	4	0.23
Impaired	0				0			
Missing	0				0			
Vaginal infection								
Normal	4	(0.2)	4	0.30	3	(0.2)	3	0.21
Impaired	0				0			
Missing	1	(1.6)	1	2.72	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acute sinusitis								
Normal	4	(0.2)	4	0.22	3	(0.2)	3	0.20
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Cellulitis								
Normal	4	(0.2)	4	0.26	7	(0.4)	8	0.61
Impaired	0				0			
Missing	0				1	(1.3)	1	2.20
Coronavirus infection								
Normal	4	(0.2)	4	0.22	4	(0.2)	6	0.42
Impaired	0				0			
Missing	0				0			
Ear infection								
Normal	4	(0.2)	4	0.26	5	(0.3)	5	0.36
Impaired	0				0			
Missing	0				0			
Periodontitis								
Normal	3	(0.2)	3	0.25	6	(0.3)	6	0.46
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Genital infection								
Normal	3	(0.2)	3	0.20	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Respiratory syncytial virus infection								
Normal	3	(0.2)	3	0.21	0			
Impaired	0				0			
Missing	0				0			
Wound infection								
Normal	3	(0.2)	3	0.24	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Erysipelas								
Normal	3	(0.2)	3	0.21	2	(0.1)	3	0.24
Impaired	0				0			
Missing	0				0			
Localised infection								
Normal	3	(0.2)	3	0.21	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Laryngitis								
Normal	3	(0.2)	3	0.17	4	(0.2)	4	0.31
Impaired	0				0			
Missing	0				0			
Vulvovaginal candidiasis								
Normal	3	(0.2)	4	0.26	3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Oral herpes								
Normal	2	(0.1)	3	0.29	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Sepsis								
Normal	2	(0.1)	2	0.19	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Paronychia								
Normal	2	(0.1)	2	0.15	2	(0.1)	3	0.29
Impaired	0				0			
Missing	0				0			
Abscess								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Osteomyelitis								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Vulvovaginal mycotic infection								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Acarodermatitis								
Normal	2	(0.1)	2	0.11	4	(0.2)	4	0.22
Impaired	0				0			
Missing	0				0			
Gastrointestinal infection								
Normal	2	(0.1)	2	0.19	3	(0.2)	4	0.22
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Furuncle								
Normal	2	(0.1)	3	0.21	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Skin infection								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Tinea infection								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Fungal skin infection								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Helicobacter infection								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Subcutaneous abscess								
Normal	2	(0.1)	2	0.15	2	(0.1)	3	0.17
Impaired	0				0			
Missing	0				0			
Onychomycosis								
Normal	2	(0.1)	2	0.15	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				1	(1.3)	1	1.44
Tonsillitis								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.15
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Candida infection								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Gingivitis								
Normal	2	(0.1)	3	0.17	4	(0.2)	4	0.35
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hordeolum								
Normal	2	(0.1)	2	0.11	3	(0.2)	3	0.24
Impaired	0				0			
Missing	0				0			
Cholecystitis infective								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Diabetic foot infection								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Infected dermal cyst								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Pharyngotonsillitis								
Normal	1	(0.1)	1	0.10	2	(0.1)	3	0.17
Impaired	0				0			
Missing	0				0			
Pneumonia viral								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Pulmonary tuberculoma								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Viral tracheitis								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Escherichia bacteraemia								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Injection site abscess								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oral candidiasis								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Postoperative wound infection								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Suspected COVID-19								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Tinea pedis								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.95
Appendicitis								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Chronic sinusitis								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Clostridium difficile colitis								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Clostridium difficile infection								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Ear infection fungal								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Gangrene								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Nail infection								
Normal	1	(0.1)	2	0.11	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Otitis externa								
Normal	1	(0.1)	1	0.05	3	(0.2)	3	0.16
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Peritonsillar abscess								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Post-acute COVID-19 syndrome								
Normal	1	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Pyelonephritis								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Skin candida								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Tinea cruris								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Abscess limb								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Anal abscess								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Enteritis infectious								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Kidney infection								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Paraspinal abscess								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Pulpitis dental								
Normal	1	(0.1)	1	0.09	4	(0.2)	4	0.35
Impaired	0				0			
Missing	0				0			
Pustule								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Tinea versicolour								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Varicella zoster virus infection								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Vulvitis								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Asymptomatic COVID-19								
Normal	1	(0.1)	1	0.06	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Bacterial infection								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Balanitis candida								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Chlamydial infection								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Chronic tonsillitis								
Normal	1	(0.1)	1	0.06	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Dermatophytosis of nail								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Escherichia urinary tract infection								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Folliculitis								
Normal	1	(0.1)	1	0.06	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Genital infection fungal								
Normal	1	(0.1)	1	0.06	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Helicobacter gastritis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Herpes simplex								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Herpes virus infection								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Infected bite								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Laryngopharyngitis								
Normal	1	(0.1)	1	0.06	1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Mastitis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Oropharyngeal candidiasis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Otitis media chronic								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Purulence								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Tracheitis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Urethritis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Viral upper respiratory tract infection								
Normal	1	(0.1)	1	0.06	3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				0			
Abdominal abscess								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Bacteraemia								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.0)	1	1.68	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bartholinitis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Body tinea								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Breast abscess								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Breast cellulitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Campylobacter gastroenteritis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Chronic hepatitis C								
Normal	0				0			
Impaired	0				1		1	
Missing	0				0			
Diverticulitis								
Normal	0				3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				2	(2.0)	2	2.02
Empyema								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Endophthalmitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Epididymitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Eye infection								
Normal	0				3	(0.2)	3	0.29
Impaired	0				0			
Missing	0				0			
Eye infection bacterial								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Fungal balanitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Gastroenteritis norovirus								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Genital candidiasis								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Giardiasis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Herpes dermatitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Herpes zoster infection neurological								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Infective iritis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Labyrinthitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lyme disease								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Oophoritis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Otitis media acute								
Normal	0				3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Parotitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Peri-implantitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Pericoronitis								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Post procedural infection								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Rotavirus infection								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Salpingitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Sinusitis bacterial								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin bacterial infection								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Soft tissue infection								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Sweat gland infection								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Urosepsis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				1	(1.3)	1	1.44
Varicella								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Viral pharyngitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Viral rhinitis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Gastrointestinal disorders								
All								
Normal	235	(13.0)	355	24.90	208	(11.7)	284	21.04
Impaired	1		1		2		2	
Missing	15	(21.3)	24	46.04	11	(11.5)	16	17.54
Diarrhoea								
Normal	78	(4.3)	95	6.74	45	(2.5)	46	3.59
Impaired	0				1		1	
Missing	6	(8.0)	7	13.40	5	(5.1)	5	5.05
Nausea								
Normal	32	(1.8)	33	2.26	25	(1.4)	26	1.92
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	5	(6.7)	5	9.50	2	(2.4)	3	3.46
Vomiting								
Normal	24	(1.3)	32	2.58	15	(0.8)	18	1.26
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Abdominal pain								
Normal	15	(0.8)	15	1.03	17	(0.9)	18	1.36
Impaired	0				0			
Missing	1	(1.6)	1	2.72	1	(1.0)	1	1.01
Constipation								
Normal	15	(0.8)	18	1.34	15	(0.8)	15	1.20
Impaired	0				0			
Missing	1	(1.6)	1	2.72	1	(1.0)	1	1.01
Gastrooesophageal reflux disease								
Normal	13	(0.7)	13	0.88	14	(0.8)	14	1.03
Impaired	0				0			
Missing	0				0			
Toothache								
Normal	12	(0.7)	12	0.74	10	(0.6)	13	1.17
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Abdominal pain upper								
Normal	11	(0.6)	13	0.95	14	(0.8)	14	0.97
Impaired	0				0			
Missing	2	(2.5)	2	2.61	1	(1.0)	2	2.02
Dental caries								
Normal	11	(0.6)	13	0.71	10	(0.6)	10	0.80
Impaired	0				0			
Missing	0				0			
Chronic gastritis								
Normal	8	(0.4)	8	0.60	4	(0.2)	4	0.27
Impaired	0				0			
Missing	0				0			
Gastritis								
Normal	7	(0.4)	7	0.54	9	(0.5)	9	0.65
Impaired	0				0			
Missing	0				0			
Dyspepsia								
Normal	7	(0.4)	7	0.54	8	(0.4)	8	0.56
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Haemorrhoids								
Normal	7	(0.4)	7	0.46	3	(0.2)	3	0.25
Impaired	0				0			
Missing	0				0			
Abdominal distension								
Normal	7	(0.4)	7	0.43	4	(0.2)	4	0.30
Impaired	0				0			
Missing	0				0			
Food poisoning								
Normal	5	(0.3)	5	0.35	4	(0.2)	5	0.44
Impaired	0				0			
Missing	0				0			
Large intestine polyp								
Normal	4	(0.2)	4	0.26	6	(0.3)	7	0.43
Impaired	0				0			
Missing	0				0			
Abdominal pain lower								
Normal	4	(0.2)	4	0.30	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Hypoaesthesia oral								
Normal	3	(0.2)	5	0.45	0			
Impaired	0				0			
Missing	0				0			
Abdominal discomfort								
Normal	3	(0.2)	3	0.21	5	(0.3)	6	0.46
Impaired	0				0			
Missing	0				0			
Diverticulum intestinal								
Normal	3	(0.2)	3	0.16	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Flatulence								
Normal	3	(0.2)	3	0.21	2	(0.1)	2	0.19
Impaired	0				0			
Missing	1	(1.6)	1	2.72	0			
Enterocolitis								
Normal	3	(0.2)	4	0.22	0			
Impaired	0				0			
Missing	0				0			
Aphthous ulcer								
Normal	2	(0.1)	2	0.11	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Inguinal hernia								
Normal	2	(0.1)	2	0.11	1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Gastric polyps								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Hiatus hernia								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Dry mouth								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Rectal polyp								
Normal	2	(0.1)	2	0.11	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Hyperaesthesia teeth								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Pancreatic failure								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Pancreatitis chronic								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Proctalgia								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Gastric dilatation								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oral pain								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Vomiting projectile								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Abdominal wall disorder								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Anal fissure								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Colitis microscopic								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Diabetic gastropathy								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Eosinophilic oesophagitis								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Gastric ulcer								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Gastrointestinal haemorrhage								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Impaired gastric emptying								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Intestinal dilatation								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Lip swelling								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Umbilical hernia								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Diverticulum								
Normal	1	(0.1)	1	0.09	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Gastrointestinal angiodysplasia								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Gingival bleeding								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Intra-abdominal haematoma								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Colitis								
Normal	1	(0.1)	1	0.06	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Colitis ischaemic								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Frequent bowel movements								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Haematochezia								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Loose tooth								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Oral discomfort								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Pancreatitis								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Tooth disorder								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Tooth impacted								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Acid peptic disease								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Anal pruritus								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Crohn's disease								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Duodenitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Enteritis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Epigastric discomfort								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Eructation								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Faeces pale								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Gastric disorder								
Normal	0				0			
Impaired	0				1		1	
Missing	0				0			
Gastric dysplasia								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.95
Gastric mucosal hypertrophy								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Gastrointestinal disorder								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Gastrointestinal inflammation								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Gastrointestinal sounds abnormal								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Gingival disorder								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Haemorrhoidal haemorrhage								
Normal	0				1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Hyperchlorhydria								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Ileus								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Irritable bowel syndrome								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Melaena								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Mesenteric panniculitis								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Noninfective gingivitis								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Odynophagia								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Oesophageal pain								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Oesophagitis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Pancreatic duct dilatation								
Normal	0				0			
Impaired	1		1		0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pancreatic pseudocyst								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Pancreatitis acute								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Peptic ulcer								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Periodontal disease								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Periodontal inflammation								
Normal	0				1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Rectal prolapse								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Small intestinal obstruction								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Stomatitis								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Tongue rough								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	2.72	0			
Ulcerative gastritis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Upper gastrointestinal haemorrhage								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Musculoskeletal and connective tissue disorders								
All								
Normal	228	(12.7)	347	24.40	230	(12.9)	315	22.78
Impaired	1		1		2		5	
Missing	17	(25.2)	21	41.14	13	(14.4)	18	24.31
Back pain								
Normal	57	(3.2)	60	4.29	57	(3.2)	59	4.44
Impaired	0				0			
Missing	5	(7.7)	6	11.37	4	(4.3)	5	8.12
Arthralgia								
Normal	38	(2.1)	45	3.18	45	(2.5)	50	3.76
Impaired	0				0			
Missing	7	(10.8)	8	15.94	3	(3.0)	4	4.98
Pain in extremity								
Normal	31	(1.7)	33	2.09	29	(1.6)	35	2.73
Impaired	0				0			
Missing	0				2	(2.4)	2	2.45
Muscle spasms								
Normal	22	(1.2)	24	1.83	7	(0.4)	7	0.47
Impaired	0				1		1	
Missing	1	(1.6)	1	2.72	1	(1.0)	1	1.01
Osteoarthritis								
Normal	21	(1.2)	23	1.57	23	(1.3)	26	1.85
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Neck pain								
Normal	14	(0.8)	14	1.06	8	(0.4)	8	0.54
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Myalgia								
Normal	14	(0.8)	14	1.09	9	(0.5)	9	0.70
Impaired	0				0			
Missing	0				0			
Intervertebral disc protrusion								
Normal	8	(0.4)	12	0.74	6	(0.3)	7	0.47
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tendonitis								
Normal	8	(0.4)	10	0.70	4	(0.2)	4	0.31
Impaired	0				0			
Missing	0				0			
Periarthritis								
Normal	8	(0.4)	8	0.53	5	(0.3)	5	0.32
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Trigger finger								
Normal	6	(0.3)	6	0.50	5	(0.3)	7	0.43
Impaired	0				0			
Missing	1	(1.0)	1	1.68	0			
Spinal osteoarthritis								
Normal	6	(0.3)	6	0.42	4	(0.2)	4	0.22
Impaired	0				1		2	
Missing	0				0			
Arthritis								
Normal	5	(0.3)	5	0.35	6	(0.3)	6	0.50
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Rotator cuff syndrome								
Normal	5	(0.3)	5	0.36	4	(0.2)	4	0.21
Impaired	0				0			
Missing	0				0			
Bursitis								
Normal	4	(0.2)	4	0.26	3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				0			
Spinal stenosis								
Normal	4	(0.2)	6	0.48	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Plantar fasciitis								
Normal	4	(0.2)	5	0.32	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Foot deformity								
Normal	3	(0.2)	5	0.31	2	(0.1)	2	0.19
Impaired	0				1		1	
Missing	0				0			
Tendon disorder								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	3	(0.2)	3	0.25	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Exostosis								
Normal	3	(0.2)	3	0.16	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Musculoskeletal stiffness								
Normal	3	(0.2)	3	0.24	1	(0.1)	1	0.06
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Intervertebral disc disorder								
Normal	3	(0.2)	3	0.20	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Osteochondrosis								
Normal	2	(0.1)	2	0.15	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				1	(1.6)	1	2.70
Joint effusion								
Normal	2	(0.1)	3	0.25	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Muscular weakness								
Normal	2	(0.1)	2	0.15	3	(0.2)	3	0.25
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Back disorder								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Coccydynia								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Musculoskeletal pain								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Chondropathy								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Polyarthritis								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Osteoporosis								
Normal	2	(0.1)	2	0.19	0			
Impaired	0				0			
Missing	0				0			
Fibromyalgia								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Groin pain								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Musculoskeletal chest pain								
Normal	2	(0.1)	2	0.11	2	(0.1)	2	0.11
Impaired	1		1		0			
Missing	0				0			
Synovial cyst								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Arthropathy								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Muscle contracture								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Pain in jaw								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Torticollis								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acquired claw toe								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Diastasis recti abdominis								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Facet joint syndrome								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Meniscopathy								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Psoriatic arthropathy								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Sacroiliitis								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Axillary mass								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Polymyalgia rheumatica								
Normal	1	(0.1)	1	0.09	1	(0.1)	3	0.29
Impaired	0				0			
Missing	0				0			
Soft tissue swelling								
Normal	1	(0.1)	3	0.28	0			
Impaired	0				0			
Missing	0				0			
Bone cyst								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Costochondritis								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Fistula								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Lumbar spinal stenosis								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Myositis								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Osteopenia								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Spinal pain								
Normal	1	(0.1)	1	0.06	4	(0.2)	4	0.27
Impaired	0				0			
Missing	0				0			
Tenosynovitis								
Normal	1	(0.1)	1	0.06	8	(0.4)	9	0.59
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Bone pain								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Cervical spinal stenosis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Dupuytren's contracture								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Flank pain								
Normal	0				5	(0.3)	6	0.41
Impaired	0				1		1	
Missing	1	(1.6)	1	2.72	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Haemarthrosis								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Intervertebral disc degeneration								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Intervertebral disc space narrowing								
Normal	0				1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Jaw disorder								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Joint swelling								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Limb deformity								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Mastication disorder								
Normal	0				1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Muscle twitching								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Neuropathic arthropathy								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Nodal osteoarthritis								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Osteochondritis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Periostitis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Rheumatoid arthritis								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Scoliosis								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Spinal retrolisthesis								
Normal	0				1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Tenosynovitis stenosans								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Vertebral osteophyte								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
General disorders and administration site conditions								
All								
Normal	188	(10.4)	295	22.33	161	(9.0)	236	16.24
Impaired	0				0			
Missing	11	(14.8)	18	32.13	13	(14.1)	25	43.26
Pyrexia								
Normal	29	(1.6)	30	2.02	32	(1.8)	34	2.53
Impaired	0				0			
Missing	3	(3.6)	3	6.08	5	(5.1)	5	5.05
Fatigue								
Normal	27	(1.5)	30	2.11	14	(0.8)	14	0.94
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oedema peripheral								
Normal	16	(0.9)	16	1.16	9	(0.5)	10	0.64
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Injection site reaction								
Normal	15	(0.8)	29	2.70	6	(0.3)	8	0.56
Impaired	0				0			
Missing	0				0			
Malaise								
Normal	13	(0.7)	15	0.99	11	(0.6)	15	1.05
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Chest pain								
Normal	12	(0.7)	12	0.87	5	(0.3)	5	0.28
Impaired	0				0			
Missing	2	(2.5)	2	2.61	0			
Pain								
Normal	10	(0.6)	11	0.90	13	(0.7)	14	1.02
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Asthenia								
Normal	10	(0.6)	10	0.76	7	(0.4)	7	0.52
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Vaccination site pain								
Normal	9	(0.5)	11	0.85	8	(0.4)	8	0.65
Impaired	0				0			
Missing	1	(1.0)	1	1.68	0			
Chest discomfort								
Normal	6	(0.3)	6	0.45	2	(0.1)	2	0.15
Impaired	0				0			
Missing	2	(3.2)	2	4.34	0			
Hunger								
Normal	6	(0.3)	7	0.43	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				1	(1.0)	1	1.95
Medical device site bruise								
Normal	5	(0.3)	7	0.46	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Medical device site reaction								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	4	(0.2)	6	0.46	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Injection site pruritus								
Normal	4	(0.2)	19	1.74	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Influenza like illness								
Normal	4	(0.2)	5	0.39	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Peripheral swelling								
Normal	4	(0.2)	5	0.36	4	(0.2)	4	0.30
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Chills								
Normal	4	(0.2)	4	0.26	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Feeling abnormal								
Normal	3	(0.2)	5	0.36	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Injection site pain								
Normal	3	(0.2)	3	0.29	11	(0.6)	29	1.81
Impaired	0				0			
Missing	0				1	(1.3)	1	2.20
Injection site bruising								
Normal	3	(0.2)	3	0.25	5	(0.3)	5	0.32
Impaired	0				0			
Missing	0				0			
Thirst								
Normal	3	(0.2)	3	0.25	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Injection site erythema								
Normal	3	(0.2)	5	0.44	3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Drug intolerance								
Normal	3	(0.2)	3	0.17	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Gait disturbance								
Normal	3	(0.2)	3	0.17	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Medical device site dermatitis								
Normal	3	(0.2)	6	0.37	6	(0.3)	12	0.69
Impaired	0				0			
Missing	1	(1.0)	1	1.68	2	(2.0)	2	2.02
Medical device site pruritus								
Normal	3	(0.2)	3	0.20	1	(0.1)	1	0.06
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Injection site haematoma								
Normal	2	(0.1)	6	0.58	2	(0.1)	6	0.57
Impaired	0				0			
Missing	0				1	(1.3)	2	4.39
Injection site haemorrhage								
Normal	2	(0.1)	2	0.19	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Injection site swelling								
Normal	2	(0.1)	2	0.19	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Discomfort								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				1	(1.6)	8	21.57
Injection site mass								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Medical device site erythema								
Normal	2	(0.1)	2	0.19	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Injection site hypersensitivity								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Medical device site haemorrhage								
Normal	2	(0.1)	2	0.11	2	(0.1)	2	0.11
Impaired	0				0			
Missing	2	(3.2)	2	3.24	0			
Multiple organ dysfunction syndrome								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Oedema								
Normal	1	(0.1)	1	0.10	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Vaccination site inflammation								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Vaccination site pruritus								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Xerosis								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Application site bruise								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Inflammation								
Normal	1	(0.1)	1	0.10	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Injection site rash								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Early satiety								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Localised oedema								
Normal	1	(0.1)	1	0.05	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Swelling face								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Vessel puncture site bruise								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Feeling hot								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Implant site pruritus								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Medical device site eczema								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Medical device site hypersensitivity								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Swelling								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Vaccination site reaction								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Application site pruritus								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Axillary pain								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Condition aggravated								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Cyst								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Death								
Normal	0				3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Facial pain								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Hernia								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Injection site dermatitis								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Injection site hypertrophy								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Injection site induration								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Injection site oedema								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Injection site urticaria								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Medical device site haematoma								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Medical device site inflammation								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Medical device site pain								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Medical device site rash								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Non-cardiac chest pain								
Normal	0				4	(0.2)	6	0.32
Impaired	0				0			
Missing	0				0			
Oedema due to renal disease								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.0)	1	1.68	0			
Procedural failure								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Systemic inflammatory response syndrome								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Vaccination site erythema								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Nervous system disorders								
All								
Normal	173	(9.6)	242	17.56	170	(9.5)	234	17.51
Impaired	0				1		1	
Missing	7	(10.5)	10	21.81	12	(13.1)	13	16.88

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Headache								
Normal	52	(2.9)	66	5.07	49	(2.7)	62	4.64
Impaired	0				0			
Missing	5	(7.3)	7	15.86	5	(5.4)	5	6.42
Dizziness								
Normal	38	(2.1)	48	3.50	35	(2.0)	42	3.28
Impaired	0				0			
Missing	0				2	(2.0)	2	2.02
Sciatica								
Normal	13	(0.7)	13	1.00	10	(0.6)	10	0.72
Impaired	0				0			
Missing	0				2	(2.0)	3	3.03
Carpal tunnel syndrome								
Normal	11	(0.6)	11	0.77	7	(0.4)	7	0.55
Impaired	0				0			
Missing	0				0			
Tremor								
Normal	11	(0.6)	12	0.74	7	(0.4)	11	0.98
Impaired	0				0			
Missing	0				1	(1.3)	1	2.20
Hypoaesthesia								
Normal	9	(0.5)	12	0.87	8	(0.4)	9	0.62
Impaired	0				0			
Missing	0				1	(1.3)	1	2.20
Paraesthesia								
Normal	8	(0.4)	9	0.53	11	(0.6)	11	0.90
Impaired	0				1		1	
Missing	0				0			
Neuropathy peripheral								
Normal	6	(0.3)	7	0.55	9	(0.5)	9	0.62
Impaired	0				0			
Missing	0				0			
Migraine								
Normal	6	(0.3)	6	0.45	3	(0.2)	3	0.25
Impaired	0				0			
Missing	0				0			
Syncope								
Normal	6	(0.3)	6	0.37	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Diabetic neuropathy								
Normal	5	(0.3)	5	0.40	12	(0.7)	12	0.91

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Dysgeusia								
Normal	3	(0.2)	3	0.21	0			
Impaired	0				0			
Missing	0				0			
Transient ischaemic attack								
Normal	3	(0.2)	3	0.21	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Amnesia								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Cerebrovascular disorder								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Memory impairment								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Carotid artery stenosis								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Neuralgia								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Post herpetic neuralgia								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Burning sensation								
Normal	2	(0.1)	2	0.11	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Tension headache								
Normal	2	(0.1)	3	0.17	0			
Impaired	0				0			
Missing	1	(1.6)	1	2.72	0			

%: Percentage of subjects with one or more events, E: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cerebral arteriosclerosis								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Vascular encephalopathy								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Vascular headache								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Cerebral atrophy								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Cluster headache								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Cognitive disorder								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Disturbance in attention								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Intracranial pressure increased								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Autonomic nervous system imbalance								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Carotid artery aneurysm								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Cervicobrachial syndrome								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Facial paralysis								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Peripheral paralysis								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Piriformis syndrome								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Somnolence								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Thalamic infarction								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Balance disorder								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Cerebral haemorrhage								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Cervical radiculopathy								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Dizziness postural								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Lumbar radiculopathy								
Normal	1	(0.1)	1	0.06	4	(0.2)	5	0.28
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Neuroglycopenia								
Normal	1	(0.1)	1	0.06	1	(0.1)	3	0.17
Impaired	0				0			
Missing	0				0			
Presyncope								
Normal	1	(0.1)	1	0.06	4	(0.2)	4	0.22
Impaired	0				0			
Missing	0				0			
Trigeminal neuralgia								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Ageusia								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Anosmia								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Basilar migraine								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Brain injury								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Carotid arteriosclerosis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Cerebral artery embolism								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Cerebral infarction								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cerebrovascular accident								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Dementia Alzheimer's type								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Essential tremor								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Facial nerve disorder								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Hemiparesis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Hypoglycaemic coma								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Hyporeflexia								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Ischaemic stroke								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Lethargy								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Loss of consciousness								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Mental impairment								
Normal	0				1	(0.1)	1	0.06

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Meralgia paraesthetica								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Morton's neuralgia								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Myelopathy								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Ophthalmic migraine								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Orthostatic tremor								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Parkinsonian gait								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Radiculopathy								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Restless legs syndrome								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Sleep deficit								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Thrombotic stroke								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vertebral artery occlusion								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
White matter lesion								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Injury, poisoning and procedural complications								
All								
Normal	158	(8.8)	193	13.84	139	(7.8)	166	12.73
Impaired	0				1		1	
Missing	6	(8.9)	11	24.89	7	(8.3)	11	15.03
Fall								
Normal	19	(1.1)	19	1.27	9	(0.5)	10	0.71
Impaired	0				0			
Missing	0				1	(1.3)	1	1.44
Contusion								
Normal	13	(0.7)	14	0.97	6	(0.3)	6	0.38
Impaired	0				0			
Missing	1	(1.6)	1	1.62	1	(1.0)	1	1.01
Vaccination complication								
Normal	13	(0.7)	13	0.84	19	(1.1)	25	1.75
Impaired	0				0			
Missing	2	(3.2)	6	16.32	2	(2.0)	2	2.02
Ligament sprain								
Normal	9	(0.5)	9	0.69	8	(0.4)	8	0.64
Impaired	0				0			
Missing	0				0			
Skin abrasion								
Normal	8	(0.4)	10	0.71	4	(0.2)	4	0.34
Impaired	0				0			
Missing	0				0			
Accidental overdose								
Normal	7	(0.4)	7	0.58	3	(0.2)	4	0.38
Impaired	0				0			
Missing	0				0			
Skin laceration								
Normal	7	(0.4)	7	0.51	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Hand fracture								
Normal	6	(0.3)	6	0.45	0			
Impaired	0				0			
Missing	0				1	(1.3)	1	1.44
Joint injury								
Normal	5	(0.3)	5	0.40	4	(0.2)	4	0.26
Impaired	0				0			
Missing	0				0			
Limb injury								
Normal	5	(0.3)	5	0.36	6	(0.3)	7	0.59
Impaired	0				0			
Missing	0				0			
Procedural pain								
Normal	4	(0.2)	4	0.30	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Road traffic accident								
Normal	4	(0.2)	4	0.30	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Rib fracture								
Normal	4	(0.2)	4	0.30	5	(0.3)	5	0.36
Impaired	0				0			
Missing	0				0			
Incorrect dose administered								
Normal	3	(0.2)	3	0.29	5	(0.3)	7	0.63
Impaired	0				0			
Missing	0				0			
Foot fracture								
Normal	3	(0.2)	3	0.25	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Arthropod bite								
Normal	3	(0.2)	3	0.29	3	(0.2)	3	0.25
Impaired	0				0			
Missing	0				0			
Tooth fracture								
Normal	3	(0.2)	3	0.25	2	(0.1)	2	0.15
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Arthropod sting								
Normal	3	(0.2)	3	0.21	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Upper limb fracture								
Normal	3	(0.2)	3	0.16	0			
Impaired	0				0			
Missing	0				0			
Overdose								
Normal	3	(0.2)	3	0.25	3	(0.2)	3	0.25
Impaired	0				0			
Missing	1	(1.6)	1	2.72	0			
Wound								
Normal	3	(0.2)	3	0.21	5	(0.3)	5	0.44
Impaired	0				0			
Missing	0				0			
Ankle fracture								
Normal	3	(0.2)	3	0.16	2	(0.1)	2	0.11
Impaired	0				1		1	
Missing	1	(1.3)	1	1.31	0			
Thermal burn								
Normal	3	(0.2)	3	0.24	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Medication error								
Normal	2	(0.1)	2	0.19	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Tendon rupture								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Back injury								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Hip fracture								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Radius fracture								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Fibula fracture								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Injury								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Meniscus injury								
Normal	2	(0.1)	2	0.11	5	(0.3)	5	0.31
Impaired	0				0			
Missing	0				0			
Accidental underdose								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Chillblains								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Extra dose administered								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Subdural haematoma								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Wrong product administered								
Normal	1	(0.1)	2	0.20	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Gun shot wound								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Ligament rupture								
Normal	1	(0.1)	2	0.19	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Procedural complication								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Animal bite								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				1	(1.6)	1	2.70
Bone contusion								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Femoral neck fracture								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Inflammation of wound								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Injury of conjunctiva								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Multiple injuries								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Muscle injury								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Neck injury								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Penile contusion								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Post procedural complication								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post procedural haematuria								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post procedural inflammation								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Radiation skin injury								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Spinal compression fracture								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Craniocerebral injury								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Face injury								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Facial bones fracture								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Subcutaneous haematoma								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Underdose								
Normal	1	(0.1)	1	0.09	5	(0.3)	5	0.44
Impaired	0				0			
Missing	0				0			
Wrist fracture								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.06

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Burn oral cavity								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Burns first degree								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Cervical vertebral fracture								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Eye injury								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Heat illness								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				2	(2.0)	3	3.03
Muscle strain								
Normal	1	(0.1)	1	0.06	4	(0.2)	4	0.30
Impaired	0				0			
Missing	0				0			
Post procedural fistula								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Post procedural haemorrhage								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Post procedural hypothyroidism								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Traumatic haematoma								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Concussion								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Crush injury								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Deafness traumatic								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Endotracheal intubation complication								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Epicondylitis								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.3)	1	1.44
Exposure to SARS-CoV-2								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Head injury								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Humerus fracture								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Intentional overdose								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Intentional product use issue								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Lower limb fracture								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Muscle contusion								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Periprocedural myocardial infarction								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Post procedural stroke								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Post procedural swelling								
Normal	0				1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Post-traumatic neck syndrome								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Product administration error								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Scar								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Scratch								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Seroma								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Soft tissue injury								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Spinal column injury								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Stab wound								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.95
Sunburn								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Tendon injury								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Tibia fracture								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Wrong dose								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Eye disorders								
All								
Normal	145	(8.1)	186	14.10	144	(8.0)	188	14.82
Impaired	0				1		1	
Missing	2	(2.6)	2	3.30	7	(8.0)	10	15.27
Diabetic retinopathy								
Normal	51	(2.8)	57	4.76	54	(3.0)	58	4.78
Impaired	0				1		1	
Missing	1	(1.0)	1	1.68	3	(3.4)	3	3.46
Cataract								
Normal	23	(1.3)	28	1.86	23	(1.3)	25	1.74
Impaired	0				0			
Missing	1	(1.6)	1	1.62	2	(2.9)	3	6.83
Macular oedema								
Normal	9	(0.5)	9	0.74	4	(0.2)	4	0.26

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Retinopathy hypertensive								
Normal	6	(0.3)	7	0.55	5	(0.3)	5	0.44
Impaired	0				0			
Missing	0				0			
Dry eye								
Normal	6	(0.3)	6	0.36	5	(0.3)	5	0.33
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Blepharitis								
Normal	5	(0.3)	5	0.32	0			
Impaired	0				0			
Missing	0				0			
Retinal haemorrhage								
Normal	4	(0.2)	4	0.34	0			
Impaired	0				0			
Missing	0				0			
Diabetic retinal oedema								
Normal	4	(0.2)	4	0.38	9	(0.5)	10	0.80
Impaired	0				0			
Missing	0				0			
Eye pain								
Normal	4	(0.2)	4	0.26	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Vision blurred								
Normal	4	(0.2)	4	0.30	5	(0.3)	5	0.36
Impaired	0				0			
Missing	0				0			
Vitreous detachment								
Normal	3	(0.2)	3	0.21	0			
Impaired	0				0			
Missing	0				0			
Glaucoma								
Normal	3	(0.2)	3	0.16	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Age-related macular degeneration								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vitreous haemorrhage								
Normal	2	(0.1)	2	0.19	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Diplopia								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Ocular hyperaemia								
Normal	2	(0.1)	3	0.28	1	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Conjunctivitis allergic								
Normal	2	(0.1)	3	0.21	0			
Impaired	0				0			
Missing	0				0			
Eye inflammation								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Ocular hypertension								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Astigmatism								
Normal	2	(0.1)	3	0.16	4	(0.2)	4	0.30
Impaired	0				0			
Missing	0				0			
Conjunctival haemorrhage								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Presbyopia								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				1	(1.0)	1	1.95
Retinal deposits								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Retinal drusen								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Retinal scar								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Non-proliferative retinopathy								
Normal	1	(0.1)	2	0.19	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Amaurosis fugax								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Angle closure glaucoma								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Arteriosclerotic retinopathy								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Conjunctival hyperaemia								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Conjunctival suffusion								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Maculopathy								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Retinal degeneration								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Visual impairment								
Normal	1	(0.1)	1	0.05	2	(0.1)	10	0.93
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Vitreous opacities								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Cataract nuclear								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Dry age-related macular degeneration								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Epiretinal membrane								
Normal	1	(0.1)	1	0.09	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Eye irritation								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Lacrimation increased								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Myopia								
Normal	1	(0.1)	1	0.09	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Retinal exudates								
Normal	1	(0.1)	1	0.09	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Retinal vein occlusion								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Acquired epiblepharon								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asthenopia								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Conjunctival erosion								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Optic disc vascular disorder								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Post thrombotic retinopathy								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Posterior capsule opacification								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Retinal aneurysm								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Retinal tear								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Chorioretinal atrophy								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Corneal bleeding								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Corneal erosion								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Cystoid macular oedema								
Normal	0				1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Dacryoadenitis acquired								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Eye discharge								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Eye pruritus								
Normal	0				1	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Eyelid oedema								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Hypermetropia								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Macular degeneration								
Normal	0				3	(0.2)	3	0.20
Impaired	0				0			
Missing	0				0			
Macular hole								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Meibomianitis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Normal tension glaucoma								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Ocular ischaemic syndrome								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Open angle glaucoma								
Normal	0				1	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Ophthalmic vein thrombosis								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Optic disc haemorrhage								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Photophobia								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Retinal artery occlusion								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Retinal detachment								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Retinal vascular disorder								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Retinopathy								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Scintillating scotoma								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Uveitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Visual acuity reduced								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): OTMTDURY CPCLGR1; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS AEDECOD CPCLGR1; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Vitreous degeneration								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Vitreous floaters								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Metabolism and nutrition disorders								
All								
Normal	117	(6.5)	146	9.98	119	(6.7)	147	10.67
Impaired	1		1		2		2	
Missing	6	(8.0)	6	9.93	4	(4.4)	9	9.95
Dyslipidaemia								
Normal	20	(1.1)	21	1.53	17	(1.0)	17	1.40
Impaired	0				0			
Missing	1	(1.0)	1	1.68	0			
Vitamin D deficiency								
Normal	15	(0.8)	15	0.86	11	(0.6)	11	0.69
Impaired	0				0			
Missing	1	(1.3)	1	1.31	1	(1.3)	1	1.44
Hyperlipidaemia								
Normal	14	(0.8)	14	0.97	13	(0.7)	13	0.88
Impaired	0				0			
Missing	0				0			
Hypoglycaemia								
Normal	13	(0.7)	19	1.58	18	(1.0)	31	2.31
Impaired	0				0			
Missing	0				2	(2.0)	5	5.05
Vitamin B12 deficiency								
Normal	10	(0.6)	10	0.54	1	(0.1)	1	0.05
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Hypertriglyceridaemia								
Normal	9	(0.5)	9	0.62	8	(0.4)	8	0.61
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hyperkalaemia								
Normal	7	(0.4)	8	0.52	10	(0.6)	10	0.76
Impaired	1		1		0			
Missing	0				0			
Hyperglycaemia								
Normal	5	(0.3)	6	0.49	13	(0.7)	13	1.02
Impaired	0				1		1	
Missing	1	(1.6)	1	2.72	0			
Iron deficiency								
Normal	5	(0.3)	5	0.27	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Gout								
Normal	4	(0.2)	5	0.27	4	(0.2)	5	0.28
Impaired	0				1		1	
Missing	0				1	(1.0)	1	1.01
Decreased appetite								
Normal	4	(0.2)	4	0.26	5	(0.3)	5	0.31
Impaired	0				0			
Missing	0				0			
Hypercholesterolaemia								
Normal	3	(0.2)	3	0.25	3	(0.2)	3	0.25
Impaired	0				0			
Missing	0				0			
Hyperuricaemia								
Normal	3	(0.2)	3	0.20	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Increased appetite								
Normal	3	(0.2)	3	0.17	6	(0.3)	7	0.59
Impaired	0				0			
Missing	0				0			
Hyponatraemia								
Normal	2	(0.1)	2	0.20	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Dehydration								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Fluid retention								
Normal	2	(0.1)	2	0.15	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Hypokalaemia								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Diabetes mellitus								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Zinc deficiency								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				1	(1.3)	1	1.44
Hypoalbuminaemia								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Diabetes mellitus inadequate control								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Folate deficiency								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Hypernatraemia								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Magnesium deficiency								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Malnutrition								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Vitamin B complex deficiency								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abnormal weight gain								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Obesity								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Appetite disorder								
Normal	0				1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Electrolyte imbalance								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Food craving								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Hyperammonaemia								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Hypercalcaemia								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Insulin resistance								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Lactic acidosis								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Lipomatosis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Metabolic acidosis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Metabolic disorder								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Respiratory, thoracic and mediastinal disorders								
All								
Normal	101	(5.6)	139	9.95	97	(5.4)	120	8.74
Impaired	0				1		1	
Missing	10	(14.4)	12	24.51	3	(3.0)	3	3.03
Cough								
Normal	21	(1.2)	22	1.54	20	(1.1)	21	1.46
Impaired	0				0			
Missing	2	(3.2)	2	4.34	0			
Oropharyngeal pain								
Normal	15	(0.8)	17	1.06	13	(0.7)	15	1.21
Impaired	0				0			
Missing	4	(5.8)	4	7.63	3	(3.0)	3	3.03
Dyspnoea								
Normal	9	(0.5)	9	0.70	13	(0.7)	14	1.03
Impaired	0				0			
Missing	0				0			
Nasal congestion								
Normal	9	(0.5)	9	0.58	4	(0.2)	4	0.22
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Rhinorrhoea								
Normal	9	(0.5)	12	0.93	7	(0.4)	7	0.47
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Sleep apnoea syndrome								
Normal	6	(0.3)	6	0.37	0			
Impaired	0				0			
Missing	1	(1.6)	1	2.72	0			
Asthma								
Normal	5	(0.3)	6	0.46	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Respiratory disorder								
Normal	4	(0.2)	4	0.35	5	(0.3)	5	0.36
Impaired	0				0			
Missing	0				0			
Sinus congestion								
Normal	4	(0.2)	5	0.36	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Epistaxis								
Normal	4	(0.2)	8	0.75	2	(0.1)	4	0.31
Impaired	0				0			
Missing	1	(1.0)	1	1.68	0			
Chronic obstructive pulmonary disease								
Normal	4	(0.2)	4	0.34	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Productive cough								
Normal	4	(0.2)	4	0.30	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Nasal septum deviation								
Normal	2	(0.1)	2	0.19	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Emphysema								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Pulmonary fibrosis								
Normal	2	(0.1)	3	0.21	0			
Impaired	0				0			
Missing	0				0			
Sinus pain								
Normal	2	(0.1)	3	0.21	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Acute respiratory failure								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.06
Impaired	0				0			
Missing	1	(1.6)	1	2.72	0			
Sneezing								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Interstitial lung disease								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Pleurisy								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Pulmonary hypertension								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Increased viscosity of upper respiratory secretion								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Rhinitis allergic								
Normal	1	(0.1)	1	0.05	5	(0.3)	9	0.67
Impaired	0				0			
Missing	0				0			
Upper respiratory tract inflammation								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Nasal obstruction								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				1		1	
Missing	0				0			
Respiratory failure								
Normal	1	(0.1)	1	0.09	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Acquired diaphragmatic eventration								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Bronchiectasis								
Normal	1	(0.1)	1	0.06	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Dyspnoea exertional								
Normal	1	(0.1)	1	0.06	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Laryngeal cyst								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Nasal dryness								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Nasal turbinate hypertrophy								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Pulmonary embolism								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Pulmonary mass								
Normal	1	(0.1)	1	0.06	4	(0.2)	4	0.30
Impaired	0				0			
Missing	0				0			
Throat irritation								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Upper-airway cough syndrome								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Acute pulmonary oedema								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Allergic bronchitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Allergic cough								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Aphonia								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Bronchitis chronic								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Bronchospasm								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	1	(1.3)	1	2.18	0			
Dry throat								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Dysphonia								
Normal	0				1	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Haemoptysis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Lung disorder								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Paranasal cyst								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Paranasal sinus discomfort								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Pleural disorder								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Pleural effusion								
Normal	0				3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Pleuritic pain								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Respiratory tract inflammation								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Skin and subcutaneous tissue disorders								
All								
Normal	97	(5.4)	105	7.28	94	(5.3)	111	7.66
Impaired	1		1		0			
Missing	1	(1.0)	1	1.68	10	(12.2)	12	18.30
Rash								
Normal	11	(0.6)	11	0.80	11	(0.6)	12	0.75
Impaired	0				0			
Missing	0				0			
Eczema								
Normal	9	(0.5)	9	0.57	5	(0.3)	5	0.40
Impaired	0				0			
Missing	1	(1.0)	1	1.68	1	(1.6)	1	2.70
Pruritus								
Normal	8	(0.4)	8	0.56	9	(0.5)	9	0.66
Impaired	0				0			
Missing	0				2	(2.6)	2	3.71
Urticaria								
Normal	7	(0.4)	7	0.54	9	(0.5)	9	0.54
Impaired	0				0			
Missing	0				0			
Hyperhidrosis								
Normal	7	(0.4)	7	0.51	4	(0.2)	4	0.30
Impaired	1		1		0			
Missing	0				1	(1.3)	1	1.44

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Alopecia								
Normal	5	(0.3)	5	0.36	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				1	(1.3)	1	2.20
Dermatitis contact								
Normal	5	(0.3)	6	0.33	8	(0.4)	8	0.54
Impaired	0				0			
Missing	0				0			
Skin ulcer								
Normal	4	(0.2)	4	0.31	5	(0.3)	5	0.44
Impaired	0				0			
Missing	0				0			
Cold sweat								
Normal	4	(0.2)	4	0.31	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Dermatitis								
Normal	3	(0.2)	3	0.21	6	(0.3)	7	0.51
Impaired	0				0			
Missing	0				0			
Night sweats								
Normal	3	(0.2)	3	0.21	0			
Impaired	0				0			
Missing	0				0			
Dry skin								
Normal	3	(0.2)	3	0.17	4	(0.2)	4	0.26
Impaired	0				0			
Missing	0				0			
Acne								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Hyperkeratosis								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Dermatitis allergic								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Ingrowing nail								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				2	(2.0)	2	2.02
Miliaria								
Normal	2	(0.1)	2	0.19	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				2	(2.0)	2	2.02
Psoriasis								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				1	(1.3)	1	2.20
Skin irritation								
Normal	2	(0.1)	3	0.17	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Intertrigo								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Umbilical haematoma								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Decubitus ulcer								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Ecchymosis								
Normal	1	(0.1)	1	0.10	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Rash erythematous								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Skin odour abnormal								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Diabetic foot								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Erythema								
Normal	1	(0.1)	1	0.05	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Livedo reticularis								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Nail bed inflammation								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Blister								
Normal	1	(0.1)	1	0.09	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Rash papular								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Angioedema								
Normal	1	(0.1)	1	0.06	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Granuloma annulare								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Lipodystrophy acquired								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Myxoid cyst								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Skin exfoliation								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Skin fissures								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Skin lesion								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Urticaria contact								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Actinic keratosis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Alopecia areata								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Asteatosis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Cold urticaria								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Dermal cyst								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Drug eruption								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Haemorrhage subcutaneous								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Hidradenitis								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Lentigo								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Leukoplakia								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Lipohypertrophy								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Macule								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Neurodermatitis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Pruritus allergic								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Purpura								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Rash maculo-papular								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Seborrhoea								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Skin discolouration								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin reaction								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Urticaria thermal								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Cardiac disorders								
All								
Normal	84	(4.7)	122	7.82	73	(4.1)	102	6.84
Impaired	0				1		2	
Missing	2	(2.9)	2	2.92	5	(6.3)	5	7.59
Coronary artery disease								
Normal	12	(0.7)	12	0.74	8	(0.4)	8	0.48
Impaired	0				1		1	
Missing	0				1	(1.6)	1	2.70
Atrial fibrillation								
Normal	12	(0.7)	13	0.76	6	(0.3)	6	0.38
Impaired	0				0			
Missing	0				0			
Acute myocardial infarction								
Normal	9	(0.5)	9	0.61	8	(0.4)	8	0.57
Impaired	0				0			
Missing	0				0			
Cardiac failure								
Normal	8	(0.4)	8	0.48	2	(0.1)	3	0.25
Impaired	0				0			
Missing	0				0			
Angina pectoris								
Normal	6	(0.3)	6	0.37	4	(0.2)	4	0.26
Impaired	0				0			
Missing	0				0			
Myocardial infarction								
Normal	6	(0.3)	6	0.46	4	(0.2)	4	0.22
Impaired	0				0			
Missing	0				0			
Palpitations								
Normal	6	(0.3)	6	0.37	5	(0.3)	5	0.32
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acute coronary syndrome								
Normal	4	(0.2)	4	0.22	0			
Impaired	0				0			
Missing	0				0			
Cardiac failure congestive								
Normal	4	(0.2)	4	0.26	2	(0.1)	3	0.29
Impaired	0				0			
Missing	0				0			
Ventricular extrasystoles								
Normal	4	(0.2)	4	0.22	2	(0.1)	3	0.16
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Myocardial ischaemia								
Normal	3	(0.2)	3	0.25	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Supraventricular extrasystoles								
Normal	3	(0.2)	3	0.25	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Mitral valve incompetence								
Normal	3	(0.2)	3	0.21	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Left ventricular hypertrophy								
Normal	3	(0.2)	3	0.17	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Angina unstable								
Normal	3	(0.2)	3	0.17	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Atrioventricular block first degree								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Bundle branch block left								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Arrhythmia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	2	(0.1)	2	0.11	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Tachycardia								
Normal	2	(0.1)	2	0.11	7	(0.4)	7	0.51
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Left ventricular dysfunction								
Normal	2	(0.1)	2	0.15	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Supraventricular tachycardia								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Cardiac failure chronic								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Coronary artery occlusion								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Aortic valve sclerosis								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Left atrial enlargement								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				1	(1.3)	1	1.44
Cardio-respiratory arrest								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Mitral valve stenosis								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Arteriosclerosis coronary artery								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Cardiac flutter								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Aortic valve incompetence								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Atrial flutter								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Atrial thrombosis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Bradycardia								
Normal	1	(0.1)	1	0.06	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Bundle branch block right								
Normal	1	(0.1)	1	0.06	6	(0.3)	7	0.47
Impaired	0				0			
Missing	0				0			
Cardiac ventricular thrombosis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Chronic coronary syndrome								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Diastolic dysfunction								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Left atrial dilatation								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pericardial effusion								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Pericarditis								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Sinus tachycardia								
Normal	1	(0.1)	1	0.06	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Tricuspid valve incompetence								
Normal	1	(0.1)	1	0.06	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Aortic valve calcification								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Atrial enlargement								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Atrioventricular block complete								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Cardiac arrest								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Cardiac dysfunction								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Cardiac failure acute								
Normal	0				0			
Impaired	0				1		1	
Missing	0				0			
Cardiac perfusion defect								
Normal	0				1	(0.1)	2	0.19

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Coronary artery stenosis								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Sinus arrhythmia								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Sinus bradycardia								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				1	(1.3)	1	1.44
Subendocardial ischaemia								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Ventricular arrhythmia								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Ventricular tachycardia								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Investigations								
All								
Normal	80	(4.5)	94	6.76	63	(3.5)	69	5.08
Impaired	0				1		1	
Missing	0				2	(2.0)	3	3.03
Weight increased								
Normal	19	(1.1)	19	1.38	16	(0.9)	16	1.19
Impaired	0				1		1	
Missing	0				1	(1.0)	1	1.01
Blood creatinine increased								
Normal	8	(0.4)	8	0.68	0			
Impaired	0				0			
Missing	0				0			
SARS-CoV-2 test positive								

%: Percentage of subjects with one or more events, E: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	7	(0.4)	7	0.59	0			
Impaired	0				0			
Missing	0				0			
Alanine aminotransferase increased								
Normal	4	(0.2)	4	0.34	0			
Impaired	0				0			
Missing	0				0			
Weight decreased								
Normal	4	(0.2)	4	0.22	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Liver function test increased								
Normal	3	(0.2)	3	0.25	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Blood alkaline phosphatase increased								
Normal	3	(0.2)	3	0.29	0			
Impaired	0				0			
Missing	0				0			
Blood triglycerides increased								
Normal	3	(0.2)	3	0.21	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Blood immunoglobulin E increased								
Normal	3	(0.2)	3	0.16	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Blood pressure increased								
Normal	3	(0.2)	3	0.21	4	(0.2)	4	0.26
Impaired	0				0			
Missing	0				0			
Occult blood								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Prostatic specific antigen increased								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Blood cholesterol increased								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Catheterisation cardiac								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Eosinophil count increased								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Liver function test abnormal								
Normal	1	(0.1)	1	0.10	1	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Arthroscopy								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Aspartate aminotransferase increased								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Blood glucose fluctuation								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Blood potassium increased								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Monocyte count decreased								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Monofilament pressure perception test								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Blood urine present								
Normal	1	(0.1)	3	0.16	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bone density decreased								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Electrocardiogram abnormal								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Electrocardiogram ST segment abnormal								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Electrocardiogram T wave inversion								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Hepatic enzyme increased								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Low density lipoprotein increased								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
QRS axis abnormal								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Thyroid function test abnormal								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Transaminases increased								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Blood creatine increased								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Blood creatine phosphokinase increased								
Normal	1	(0.1)	1	0.06	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Body temperature increased								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Glycosylated haemoglobin increased								
Normal	1	(0.1)	1	0.06	2	(0.1)	3	0.16
Impaired	0				0			
Missing	0				0			
International normalised ratio abnormal								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
International normalised ratio decreased								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
International normalised ratio increased								
Normal	1	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Red blood cell count decreased								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Transferrin saturation decreased								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Amylase increased								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Antinuclear antibody positive								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Blood glucose decreased								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood glucose increased								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Blood pressure decreased								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Breath sounds abnormal								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Carbohydrate antigen 19-9 increased								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Cardiac murmur								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Cardiac stress test abnormal								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Ejection fraction decreased								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Electrocardiogram P wave biphasic								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Electrocardiogram repolarisation abnormality								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Electrocardiogram ST segment depression								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Free fatty acids increased								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Glomerular filtration rate decreased								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Grip strength decreased								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Haematocrit increased								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Haemoglobin decreased								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Haemoglobin increased								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Intraocular pressure increased								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Lipase increased								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Lipids increased								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Platelet count decreased								
Normal	0				3	(0.2)	3	0.29
Impaired	0				0			
Missing	0				0			
Vitamin D decreased								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Vascular disorders								
All								
Normal	72	(4.0)	81	5.66	73	(4.1)	90	6.63
Impaired	0				1		3	
Missing	1	(1.6)	1	1.62	2	(2.7)	2	2.88
Hypertension								
Normal	31	(1.7)	31	2.23	33	(1.8)	37	2.79
Impaired	0				1		2	
Missing	1	(1.6)	1	1.62	1	(1.3)	1	1.44
Hypotension								
Normal	6	(0.3)	6	0.41	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Peripheral arterial occlusive disease								
Normal	4	(0.2)	5	0.36	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Arteriosclerosis								
Normal	3	(0.2)	3	0.16	7	(0.4)	7	0.51
Impaired	0				0			
Missing	0				0			
Superficial vein thrombosis								
Normal	3	(0.2)	3	0.16	0			
Impaired	0				0			
Missing	0				0			
Peripheral coldness								
Normal	3	(0.2)	3	0.17	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Orthostatic hypotension								
Normal	2	(0.1)	2	0.19	0			
Impaired	0				0			
Missing	0				0			
Haematoma								
Normal	2	(0.1)	2	0.15	3	(0.2)	3	0.25
Impaired	0				0			
Missing	0				0			
Peripheral artery stenosis								
Normal	2	(0.1)	5	0.41	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Peripheral venous disease								
Normal	2	(0.1)	2	0.15	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Blood pressure inadequately controlled								
Normal	2	(0.1)	2	0.11	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Aortic arteriosclerosis								
Normal	2	(0.1)	2	0.11	4	(0.2)	4	0.35
Impaired	0				0			
Missing	0				0			
Deep vein thrombosis								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Diabetic vascular disorder								
Normal	1	(0.1)	1	0.10	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Hypertensive crisis								
Normal	1	(0.1)	1	0.10	2	(0.1)	4	0.35
Impaired	0				0			
Missing	0				0			
Arterial insufficiency								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Varicose ulceration								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Hot flush								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Venous stenosis								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Aortic stenosis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				1		1	
Missing	0				0			
Brachiocephalic arteriosclerosis								
Normal	1	(0.1)	1	0.06	3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				0			
Flushing								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Hypertensive urgency								
Normal	1	(0.1)	1	0.06	2	(0.1)	3	0.20
Impaired	0				0			
Missing	0				0			
Peripheral artery occlusion								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Peripheral vascular disorder								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Thrombosis								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Varicose vein								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				1	(1.3)	1	1.44
Aneurysm								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Aortic aneurysm								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Aortic dilatation								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Blood pressure fluctuation								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Iliac artery stenosis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Intermittent claudication								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Macroangiopathy								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Neovascularisation								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Peripheral artery aneurysm								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Peripheral ischaemia								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Phlebitis								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Thrombophlebitis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			

Renal and urinary disorders

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
Normal	50	(2.8)	61	4.44	44	(2.5)	57	3.75
Impaired	1		1		1		1	
Missing	0				6	(7.3)	6	9.44
Renal cyst								
Normal	6	(0.3)	6	0.45	4	(0.2)	4	0.26
Impaired	1		1		0			
Missing	0				0			
Pollakiuria								
Normal	5	(0.3)	5	0.44	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Nephrolithiasis								
Normal	5	(0.3)	5	0.27	4	(0.2)	6	0.45
Impaired	0				0			
Missing	0				0			
Chronic kidney disease								
Normal	4	(0.2)	4	0.35	2	(0.1)	2	0.11
Impaired	0				1		1	
Missing	0				2	(2.6)	2	3.71
Dysuria								
Normal	4	(0.2)	5	0.32	3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				1	(1.6)	1	2.70
Renal impairment								
Normal	4	(0.2)	4	0.30	3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				0			
Acute kidney injury								
Normal	3	(0.2)	3	0.25	5	(0.3)	5	0.27
Impaired	0				0			
Missing	0				0			
Ureterolithiasis								
Normal	3	(0.2)	3	0.21	3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				0			
Diabetic nephropathy								
Normal	3	(0.2)	3	0.20	2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Nocturia								
Normal	2	(0.1)	2	0.11	2	(0.1)	2	0.11

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Urine odour abnormal								
Normal	2	(0.1)	2	0.15	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Haematuria								
Normal	1	(0.1)	2	0.20	4	(0.2)	4	0.26
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Chromaturia								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Renal failure								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Hypertonic bladder								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Proteinuria								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Renal pain								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Urinary incontinence								
Normal	1	(0.1)	1	0.05	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Urinary retention								
Normal	1	(0.1)	1	0.05	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Urinary tract disorder								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bladder prolapse								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Hydronephrosis								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Nephrotic syndrome								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Polyuria								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Urethral stenosis								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Calculus urinary								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Microalbuminuria								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Pyelocaliectasis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Renal colic								
Normal	1	(0.1)	1	0.06	3	(0.2)	3	0.25
Impaired	0				0			
Missing	0				0			
Bladder mass								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Cystitis haemorrhagic								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Hydrocalyx								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Micturition urgency								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Nephropathy								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Renal mass								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Strangury								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Stress urinary incontinence								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Urinary tract inflammation								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Urinary tract obstruction								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Psychiatric disorders								
All								
Normal	34	(1.9)	37	2.48	34	(1.9)	36	2.73
Impaired	0				1		1	
Missing	2	(2.8)	3	5.33	2	(2.6)	2	3.71

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Insomnia								
Normal	10	(0.6)	10	0.71	4	(0.2)	5	0.36
Impaired	0				0			
Missing	0				2	(2.6)	2	3.71
Depression								
Normal	8	(0.4)	8	0.52	8	(0.4)	8	0.61
Impaired	0				1		1	
Missing	0				0			
Sleep disorder								
Normal	4	(0.2)	4	0.22	4	(0.2)	4	0.38
Impaired	0				0			
Missing	0				0			
Anxiety								
Normal	4	(0.2)	4	0.26	6	(0.3)	6	0.33
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Mental status changes								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Agitation								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Drug abuse								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Irritability								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	1	(1.3)	1	1.31	0			
Adjustment disorder with mixed anxiety and depressed mood								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Disorientation								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Listless								

%: Percentage of subjects with one or more events, E: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Post-traumatic stress disorder								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Stress								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Depressed mood								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Nightmare								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Adjustment disorder								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	2.72	0			
Adjustment disorder with depressed mood								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Affect lability								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Anxiety disorder								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Bruxism								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Drug dependence								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Emotional distress								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Fear								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Major depression								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Mixed anxiety and depressive disorder								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Mood swings								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Persistent depressive disorder								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Phobia								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Blood and lymphatic system disorders								
All								
Normal	32	(1.8)	34	2.49	23	(1.3)	23	1.56
Impaired	1		1		2		2	
Missing	0				5	(5.9)	5	7.93
Anaemia								
Normal	19	(1.1)	21	1.60	9	(0.5)	9	0.58
Impaired	0				1		1	
Missing	0				4	(4.9)	4	6.92
Eosinophilia								
Normal	3	(0.2)	3	0.21	2	(0.1)	2	0.15

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Lymphadenopathy								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Blood loss anaemia								
Normal	1	(0.1)	1	0.10	2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Lymphadenopathy mediastinal								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Leukopenia								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Leukocytosis								
Normal	1	(0.1)	1	0.05	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Splenomegaly								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Iron deficiency anaemia								
Normal	1	(0.1)	1	0.06	2	(0.1)	2	0.15
Impaired	1		1		1		1	
Missing	0				0			
Polycythaemia								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Thrombocytopenia								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Hypochromic anaemia								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normocytic anaemia								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Pancytopenia								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Thrombocytosis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
Normal	29	(1.6)	37	2.56	25	(1.4)	38	2.53
Impaired	0				0			
Missing	2	(3.2)	2	3.24	2	(2.0)	2	2.96
Colon adenoma								
Normal	3	(0.2)	3	0.24	0			
Impaired	0				0			
Missing	0				0			
Eye naevus								
Normal	2	(0.1)	3	0.21	0			
Impaired	0				0			
Missing	0				0			
Adenocarcinoma pancreas								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Colorectal cancer								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Pancreatic neoplasm								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Metastases to liver								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.05

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Seborrhoeic keratosis								
Normal	2	(0.1)	3	0.17	0			
Impaired	0				0			
Missing	0				0			
Osteoma								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Small cell lung cancer								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Bladder papilloma								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Lung cancer metastatic								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Skin papilloma								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Bladder cancer								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Invasive ductal breast carcinoma								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Invasive lobular breast carcinoma								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Lipoma								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pancreatic carcinoma								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Renal neoplasm								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Squamous cell carcinoma of skin								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Chronic myeloid leukaemia								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Gastric cancer								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Basal cell carcinoma								
Normal	1	(0.1)	1	0.06	3	(0.2)	3	0.17
Impaired	0				0			
Missing	0				0			
Glioblastoma multiforme								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Haemangioma of liver								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Oral fibroma								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Prostate cancer								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Salivary gland neoplasm								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Acrochordon								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Adenocarcinoma of colon								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Adrenal adenoma								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Benign renal neoplasm								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Bowen's disease								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Breast cancer								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Breast cancer metastatic								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Colon cancer								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Colon cancer stage II								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Dysplastic naevus								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Endometrial adenocarcinoma								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Gastrointestinal tract adenoma								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Hepatocellular carcinoma								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Invasive breast carcinoma								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Lung adenocarcinoma								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Lymphangioma								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Malignant melanoma								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Malignant melanoma in situ								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Malignant peritoneal neoplasm								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Metastases to bone marrow								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Metastases to lymph nodes								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Myxoma								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Neoplasm skin								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Ovarian cancer metastatic								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Pancreatic carcinoma metastatic								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.95
Prostatic adenoma								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Renal cell carcinoma								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Renal hamartoma								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Small intestine neuroendocrine tumour								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Uterine cancer								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Uterine leiomyoma								
Normal	0				3	(0.2)	3	0.21

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Impaired	0				0			
Missing	0				0			
Reproductive system and breast disorders								
All								
Normal	28	(1.6)	28	1.94	20	(1.1)	24	1.56
Impaired	0				0			
Missing	1	(1.6)	1	1.62	3	(3.0)	3	3.03
Benign prostatic hyperplasia								
Normal	5	(0.3)	5	0.35	3	(0.2)	3	0.21
Impaired	0				0			
Missing	0				0			
Erectile dysfunction								
Normal	5	(0.3)	5	0.31	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Intermenstrual bleeding								
Normal	2	(0.1)	2	0.19	0			
Impaired	0				0			
Missing	0				0			
Uterine polyp								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Breast pain								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Menstruation delayed								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Prostatic calcification								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Atrophic vulvovaginitis								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Ejaculation failure								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Menstruation irregular								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Pelvic discomfort								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Cervical polyp								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Prostatitis								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Breast mass								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Menopausal symptoms								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Ovarian cyst								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Pruritus genital								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Vulvovaginal pruritus								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Colpocele								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Dysmenorrhoea								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Galactorrhoea								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Genital prolapse								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Menopausal disorder								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Penile rash								
Normal	0				1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Testicular cyst								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Uterine enlargement								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Uterine prolapse								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Vaginal discharge								
Normal	0				2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Vaginal haemorrhage								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vulvovaginal dryness								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Ear and labyrinth disorders								
All								
Normal	26	(1.4)	29	1.90	21	(1.2)	22	1.60
Impaired	0				0			
Missing	0				1	(1.6)	1	2.70
Vertigo								
Normal	10	(0.6)	11	0.76	7	(0.4)	8	0.54
Impaired	0				0			
Missing	0				1	(1.6)	1	2.70
Ear pain								
Normal	5	(0.3)	5	0.35	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Deafness bilateral								
Normal	2	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			
Vertigo positional								
Normal	2	(0.1)	2	0.11	1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Hypoacusis								
Normal	2	(0.1)	2	0.15	3	(0.2)	3	0.16
Impaired	0				0			
Missing	0				0			
Tinnitus								
Normal	2	(0.1)	2	0.11	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Cerumen impaction								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
External ear pain								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Meniere's disease								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Ear inflammation								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Eustachian tube dysfunction								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Deafness unilateral								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Ear discomfort								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Middle ear inflammation								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Motion sickness								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Presbyacusis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Hepatobiliary disorders								
All								
Normal	18	(1.0)	24	1.61	20	(1.1)	24	1.73
Impaired	1		1		1		1	
Missing	0				0			
Hepatic steatosis								
Normal	8	(0.4)	8	0.48	9	(0.5)	9	0.62
Impaired	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Missing	0				0			
Cholelithiasis								
Normal	3	(0.2)	3	0.16	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Hepatomegaly								
Normal	2	(0.1)	2	0.15	0			
Impaired	0				0			
Missing	0				0			
Cholecystitis chronic								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Cholecystitis								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Hepatic function abnormal								
Normal	1	(0.1)	1	0.10	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Hepatic mass								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Alcoholic liver disease								
Normal	1	(0.1)	1	0.09	0			
Impaired	0				0			
Missing	0				0			
Gallbladder polyp								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Gallbladder cholesterolosis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Hypertransaminasaemia								
Normal	1	(0.1)	2	0.11	0			
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Liver disorder								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Non-alcoholic steatohepatitis								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Bile duct stone								
Normal	0				1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Biliary colic								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Biliary dyskinesia								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Hepatic cirrhosis								
Normal	0				1	(0.1)	1	0.10
Impaired	0				1		1	
Missing	0				0			
Hepatic cyst								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Hyperplastic cholecystopathy								
Normal	0				0			
Impaired	1		1		0			
Missing	0				0			
Nonalcoholic fatty liver disease								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Steatohepatitis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Immune system disorders								
All								
Normal	11	(0.6)	12	0.83	13	(0.7)	14	1.11
Impaired	0				0			
Missing	1	(1.6)	1	2.72	2	(2.0)	2	2.96
Seasonal allergy								
Normal	7	(0.4)	7	0.43	7	(0.4)	7	0.56
Impaired	0				0			
Missing	1	(1.6)	1	2.72	1	(1.0)	1	1.01
Drug hypersensitivity								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Hypersensitivity								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Food allergy								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Anaphylactic reaction								
Normal	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Allergy to arthropod bite								
Normal	1	(0.1)	1	0.06	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				1	(1.0)	1	1.95
Allergy to arthropod sting								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Immunisation reaction								
Normal	0				1	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Congenital, familial and genetic disorders								
All								
Normal	6	(0.3)	6	0.50	5	(0.3)	5	0.31
Impaired	0				0			
Missing	0				0			
Type V hyperlipidaemia								
Normal	3	(0.2)	3	0.25	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Corneal dystrophy								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Cystic fibrosis lung								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Hydrocele								
Normal	1	(0.1)	1	0.06	0			
Impaired	0				0			
Missing	0				0			
Atrial septal defect								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Congenital syphilitic osteochondritis								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Hypertrophic cardiomyopathy								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Myotonic dystrophy								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Endocrine disorders								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
Normal	6	(0.3)	6	0.42	15	(0.8)	15	1.07
Impaired	0				1		1	
Missing	0				2	(2.0)	2	2.02
Hypothyroidism								
Normal	2	(0.1)	2	0.15	3	(0.2)	3	0.21
Impaired	0				1		1	
Missing	0				0			
Thyroid mass								
Normal	2	(0.1)	2	0.11	2	(0.1)	2	0.15
Impaired	0				0			
Missing	0				0			
Hypogonadism								
Normal	1	(0.1)	1	0.10	1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Autoimmune thyroiditis								
Normal	1	(0.1)	1	0.05	0			
Impaired	0				0			
Missing	0				0			
Adrenal mass								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Adrenocortical insufficiency acute								
Normal	0				2	(0.1)	2	0.19
Impaired	0				0			
Missing	0				0			
Goitre								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01
Hyperplasia adrenal								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Hyperprolactinaemia								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hyperthyroidism								
Normal	0				2	(0.1)	2	0.11
Impaired	0				0			
Missing	0				0			
Inappropriate antidiuretic hormone secretion								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Secondary hypogonadism								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Surgical and medical procedures								
All								
Normal	3	(0.2)	3	0.25	5	(0.3)	5	0.36
Impaired	0				0			
Missing	1	(1.6)	1	1.62	1	(1.0)	1	1.01
Shoulder operation								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Tooth extraction								
Normal	1	(0.1)	1	0.10	0			
Impaired	0				0			
Missing	0				0			
Cardiac pacemaker replacement								
Normal	1	(0.1)	1	0.05	1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Knee operation								
Normal	0				0			
Impaired	0				0			
Missing	1	(1.6)	1	1.62	0			
Large intestinal polypectomy								
Normal	0				0			
Impaired	0				0			
Missing	0				1	(1.0)	1	1.01


%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Removal of foreign body								
Normal	0				1	(0.1)	1	0.06
Impaired	0				0			
Missing	0				0			
Skin neoplasm excision								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Spinal operation								
Normal	0				1	(0.1)	1	0.05
Impaired	0				0			
Missing	0				0			
Toe amputation								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Social circumstances								
All								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			
Menopause								
Normal	0				1	(0.1)	1	0.10
Impaired	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.85 Adverse events by baseline hepatic function and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital. Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages were only derived if all trials could contribute. Safety analysis set. MedDRA version 24.1. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): CPCLGR1; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS CPCLGR1; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:00:29 - faedotgrp/faesocgrphepaticdotontp3asas.png

7.7.86 Adverse events by baseline hepatic function and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital, Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages were only derived if all trials could contribute. Safety analysis set. MedDRA version 24.1. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): CPCLGR1; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS CPCLGR1; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:00:33 - faedotgrp/faesocgrphepaticdotontt2dsas.png

7.7.87 Adverse events by baseline hepatic function and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects. Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages were only derived if all trials could contribute. Safety analysis set. MedDRA version 24.1. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): CPCLGR1; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD CPCLGR1; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:00:37 - faedotgrp/faept5pctgrphepaticdotontp3asas.png

7.7.88 Adverse events by baseline hepatic function and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool



% of subjects: Percentage of subjects with one or more events, N: Number of subjects, Impaired hepatic function is defined as having a total score of >2 according to a modified Child-Pugh classification based on low serum albumin and/or increased bilirubin. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages were only derived if all trials could contribute. Safety analysis set. MedDRA version 24.1. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): CPCLGR1; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD CPCLGR1; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:00:43 - faedotgrp/faept5pctgrphepaticdotontt2dsas.png

7.7.89 Adverse events by COVID-19 trial co-participation - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

There is no data for this output

adsl.xpt; variable(s): OTMTDURY C19TFL; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT C19TFL; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:09:39 - taesumgrp/taegrpcov19sumontp3asas.txt

7.7.90 Adverse events by COVID-19 trial co-participation - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

There is no data for this output

adsl.xpt; variable(s): OTMTDURY C19TFL; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AESER ASEV AREL1 ATECH1 AOUT C19TFL; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:09:40 - taesumgrp/taegrpcov19sumontt2dsas.txt

7.7.91 Adverse events by COVID-19 trial co-participation, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

```
There is no data for this output
```

```
                      adsl.xpt; variable(s): OTMTDURY C19TFL; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS AEDECOD C19TFL; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) ==
                                                                                "Y" & (ANL06FL) == "Y"
                                                                nn1436/nn1436-iss/submission_20221024_er
                                                05DEC2022:13:05:52 - taesocptgrp/taesocptgrpcov19sumontp3asas.txt
```

7.7.92 Adverse events by COVID-19 trial co-participation, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

```
There is no data for this output
```

```
                      adsl.xpt; variable(s): OTMTDURY C19TFL; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS AEDECOD C19TFL; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) ==
                                                                                "Y" & (ANL06FL) == "Y"
                                                                nn1436/nn1436-iss/submission_20221024_er
                                                05DEC2022:13:05:53 - taesocptgrp/taesocptgrpcov19sumontt2dsas.txt
```

7.7.93 Adverse events by COVID-19 trial co-participation and system organ class - on-treatment/main-on- treatment - dot plot - safety analysis set - phase 3a pool

```
There is no data for this output
```

```
                                adsl.xpt; variable(s): C19TFL; criteria: POOLGR2N == 2 & SAFFL == "Y"
  adae.xpt; variable(s): AEBODSYS C19TFL; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" &
                                                                                    (ANL06FL) == "Y"
                                                                nn1436/nn1436-iss/submission_20221024_er
                                                    05DEC2022:13:00:46 - faedotgrp/faesocgrpcov19dotontp3asas.txt
```

7.7.94 Adverse events by COVID-19 trial co-participation and system organ class - on-treatment/main-on- treatment - dot plot - safety analysis set - T2D pool

```
There is no data for this output
```

```
                                adsl.xpt; variable(s): C19TFL; criteria: POOLGR1N == 1 & SAFFL == "Y"
  adae.xpt; variable(s): AEBODSYS C19TFL; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" &
                                                                                    (ANL06FL) == "Y"
                                                                nn1436/nn1436-iss/submission_20221024_er
                                                    05DEC2022:13:00:48 - faedotgrp/faesocgrpcov19dotontt2dsas.txt
```

7.7.95 Adverse events by COVID-19 trial co-participation and preferred term - most frequent [>=5%] - on- treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool

```
There is no data for this output
```

```
                                adsl.xpt; variable(s): C19TFL; criteria: POOLGR2N == 2 & SAFFL == "Y"
   adae.xpt; variable(s): AEDECOD C19TFL; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" &
                                                                                    (ANL06FL) == "Y"
                                                                nn1436/nn1436-iss/submission_20221024_er
                                                    05DEC2022:13:00:50 - faedotgrp/faept5pctgrpcov19dotontp3asas.txt
```

7.7.96 Adverse events by COVID-19 trial co-participation and preferred term - most frequent [>=5%] - on- treatment/main-on-treatment - dot plot - safety analysis set - T2D pool

---

There is no data for this output

---

adsl.xpt; variable(s): C19TFL; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD C19TFL; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:00:52 - faedotgrp/faept5pctgrpcov19dotontt2dsas.txt